Page last updated: 2024-09-03

imatinib mesylate and Ph 1 Chromosome

imatinib mesylate has been researched along with Ph 1 Chromosome in 388 studies

Research

Studies (388)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (1.03)	18.2507
2000's	186 (47.94)	29.6817
2010's	155 (39.95)	24.3611
2020's	43 (11.08)	2.80

Authors

Authors	Studies
Gao, L; Peng, ZY; Ren, MQ; Shi, G; Tian, ZG; Yuan, Z	1
Atsuta, Y; Cho, R; Dobashi, N; Doki, N; Fujisawa, S; Fujita, H; Hagihara, M; Hata, T; Hatta, Y; Hayakawa, F; Hiramoto, N; Hirano, D; Ishikawa, Y; Ito, T; Kako, S; Kamae, T; Kobayashi, Y; Matsuda, M; Miyazaki, Y; Naoe, T; Nishiwaki, S; Ohtake, S; Onoda, M; Ozawa, Y; Sakura, T; Suehiro, Y; Sugiura, I; Tanaka, M; Taniguchi, Y; Tsuji, M; Ueda, Y; Yokoyama, H	1
Baek, DW; Choi, Y; Jung, SH; Kim, DY; Koh, Y; Moon, JH; Sohn, SK; Yhim, HY	1
An, F; Brümmendorf, TH; Cortes, JE; Crescenzo, RJ; Ferdinand, R; Gambacorti-Passerini, C; Kim, DW; Kota, V; Leip, E; Lipton, JH	1
Adachi, S; Hirai, H; Hirata, M; Imai, Y; Kamikubo, Y; Kataoka, TR; Kato, I; Kimura, S; Koyama, A; Kubota, H; Maeda, S; Masuda, T; Matsuo, H; Mitsuda, Y; Mizuta, S; Morita, K; Naka, K; Nakahata, T; Sakuramoto, N; Shimada, S; Sugiyama, H; Suzuki, K; Takita, J; Tanaka, K	1
Ashraf, S; Bachiashvili, K; Bhatia, R; Jamy, O; Rangaraju, S; Vachhani, P; Wolfson, J	1
Roskoski, R	1
Andrade, A; Bass, F; Benavente, R; Cabrera, ME; Cid, F; Encina, A; Molina, J; Monardes, V; Puga, B	1
Badell Serra, I; de la Fuente Regaño, L; Díaz de Heredia Rubio, C; Galán Gómez, V; González Vicent, M; Isabel Pascual Martínez, A; López Duarte, M; María Fernández, J; María Pérez Hurtado, J; Pérez-Martínez, A; Rodríguez Villa, A; Soledad Maldonado Regalado, M	1
Akahane, K; Goi, K; Harama, D; Inukai, T; Kagami, K; Kasai, S; Nguyen, TTT; Tamai, M; Watanabe, A	1
Alonso, N; Bermúdez, A; Cano-Ferri, I; Esteban, D; Esteve, J; García-Calduch, O; García-Fortes, M; García-Sanz, R; Genescà, E; González-Campos, J; Martínez, P; Martínez-Lopez, J; Mercadal, S; Montesinos, P; Ribera, J; Ribera, JM; Torrent, A	1
Haddad, FG; Jabbour, E; Kantarjian, H; Short, NJ	1
Achakzai, NM; Ali, I; Asif, M; Baloch, Z; Hussain, A; Rasool, M	1
Haddad, FG; Short, NJ	1
Cao, W; Jia, L; Liu, L; Qiu, Y; Shi, L; Wang, X; Xiao, Y; Yu, Y; Zhang, H; Zhang, R	1
Chen, C; Li, X; Qi, J; Yongjing, W	1
Mori, N; Motoji, T; Okada, M; Sameshima, Y; Shiseki, M; Tanaka, J	1
Altamura, H; Braley, J; Branford, S; Feng, J; Grigg, AP; Hughes, TP; Kenyon, RR; King, RM; Kok, CH; Lin, M; Mills, AK; Pagani, IS; Ross, DM; Saunders, V; Schreiber, AW; Schwarer, AP; Scott, HS; Shahrin, N; Shanmuganathan, N; Thomson, D; Wadham, C; Wang, P; Yeung, DT; Yong, ASM	1
Abdo, ARN; Bendit, I; Ferreira, APS; Ferreira, MPS; Giorgi, RR; Maciel, FVR; Nardinelli, L; Rego, EM; Rocha, V; Ruiz, ARL; Santos, FM; Seguro, FS	1
Dobi, B; Freitag, A; Patos, P; Prawitz, T; Ribera, JM; Rizzo, F; Sabatelli, L; Sharma, A	1
Chen, B; Guan, J; Ma, J	1
Chen, M; Lin, Y; Liu, L; Lu, X; Ni, J; Yang, H; Zhang, L	1
Biondi, A; Borowitz, MJ; Cario, G; Carroll, AJ; Cazzaniga, G; Devidas, M; Gastier-Foster, JM; Heerema, NA; Hunger, SP; Loh, ML; Martin-Regueira, P; Moorman, AV; Raetz, EA; Reshmi, SC; Saha, V; Schrappe, M; Schultz, KR; Silverman, LB; Slayton, WB; Tran, TH; Valsecchi, MG	1
Assouline, S; Brümmendorf, TH; Castagnetti, F; Cortes, JE; Gambacorti-Passerini, C; Kota, V; Leip, E; Lipton, JH; Viqueira, A	1
Ansari, S; Verma, M	1
Haddad, FG; Issa, G; Jabbour, E; Jain, N; Kantarjian, H; Sasaki, K; Short, NJ	1
Akahoshi, Y; Atsuta, Y; Fukuda, T; Ichinohe, T; Kako, S; Kanda, Y; Mizuta, S; Nakamae, H; Nishiwaki, S; Ohashi, K; Onizuka, M; Ozawa, Y; Shiratori, S; Takahashi, S; Tanaka, M; Uchida, N	1
Barberi, W; Cazzaniga, G; Chiaretti, S; De Propris, MS; Del Giudice, I; Della Starza, I; Fazio, F; Fazio, G; Foà, R; Guarini, A; Mancini, F; Messina, M; Mohamed, S; Moleti, ML; Testi, AM	1
Asou, N; Fujioka, I; Fujita, H; Hatta, Y; Iriyama, N; Ishikawa, M; Kawaguchi, T; Kimura, Y; Kizaki, M; Komatsu, N; Nakazato, T; Sato, E; Sugimoto, KJ; Takaku, T; Tokuhira, M	1
Gotoh, A; Moriyama, M; Okabe, S; Tanaka, Y	1
Rabin, KR	1
Cai, J; Chen, X; Cheng, C; Fang, Y; Gao, J; Hu, Q; Hu, S; Jeha, S; Jiang, H; Jin, R; Ju, X; Li, C; Li, CK; Liang, C; Pan, K; Pei, D; Pui, CH; Shen, S; Sun, L; Tang, J; Tian, X; Wang, N; Wu, X; Yang, JJ; Yang, M; Yu, J; Zhai, X; Zhang, H; Zhu, X; Zhu, Y	1
Killock, D	1
Jin, J; Li, XY; Meng, HT; Qian, JJ; Tong, HY; Wang, SS; Yang, M; Ye, XJ; Yu, WJ; Zhang, Y; Zhu, HH	1
Bonifacio, M; Candoni, A; Chiaretti, S; Ciccone, M; Curti, A; Fava, C; Ferrara, F; Foà, R; Pizzolo, G	1
Burke, MJ; Egelund, TA; Katzenstein, HM; Liberio, N; Ng, JS; Pommert, L; Siver, MJ	1
Hatta, Y; Hayakawa, F; Yamazaki, E	1
Feng, J; Gao, S; Liang, B; Shi, Y; Wu, D; Xing, C; Xu, W; Zhou, B; Zhou, Y	1
Sasaki, K	1
Dobashi, N	1
Deng, L; Fan, Z; Huang, F; Jin, H; Li, X; Liang, X; Lin, D; Lin, R; Liu, H; Liu, Q; Ma, L; Nie, D; Sun, J; Xu, D; Xu, N; Xuan, L; Ye, J; Zhang, Y	1
Chen, M; Lin, Y; Tengwang, T; Zhang, L; Zhu, Y	1
Bagal, B; Bonda, A; Gokarn, A; Jain, H; Khattry, N; Patkar, N; Punatar, S; Sengar, M; Shetty, D; Subramanian, P; Talker, E; Talker, J	1
Adachi, S; Hiramatsu, H; Kamitori, T; Kato, I; Mikami, T; Ogata, H; Oiki, N; Okamoto, S; Okamoto, T; Takita, J; Tanaka, K; Tasaka, K; Umeda, K	1
Bergsagel, J; Castellino, SM; Effinger, KE; Lewis, RW; Mertens, A; Patterson, B; Sabnis, HS; Sakamoto, KM; Schapira, L; Smith, SM	1
Jin, J; Li, C; Lou, Y; Ma, Y; Mai, W; Mao, L; Meng, H; Qian, W; Suo, S; Tong, H; Wei, J; Xu, W; Yu, W	1
Chen, H; Chen, YH; Huang, XJ; Lai, YY; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH	1
Akram, M; Quraishi, AM; Saeed, S; Tahir, M	1
Asemissen, AM; Dierlamm, J	1
Jabbour, E; Kantarjian, H; Ravandi, F; Short, NJ	1
Maese, L; Raetz, EA; Tasian, SK	1
Bardy-Bouxin, N; Brümmendorf, TH; Chuah, C; Cortes, JE; Deininger, MW; Dyagil, I; Gambacorti-Passerini, C; Garcia-Gutierrez, V; Glushko, N; Hochhaus, A; Jeynes-Ellis, A; Kim, DW; le Coutre, P; Leip, E; Mauro, MJ; Milojkovic, D; Reilly, L	1
Chen, H; Huang, XJ; Jia, JS; Jiang, B; Jiang, H; Jiang, Q; Liu, KY; Qin, YZ; Ruan, GR; Wang, J; Xu, LP; Zhang, XH; Zhao, T	1
Cortelezzi, A; Fracchiolla, NS; Sciumè, M	1
Koya, J; Kurokawa, M; Morita, K; Nakamura, F; Toya, T	1
Li, Z; Song, YP; Yu, FK; Zhang, SJ; Zhang, YL; Zhao, HF; Zhao, JJ; Zhou, J; Zu, YL	1
Dobashi, N; Doki, N; Hatta, Y; Hayakawa, F; Ito, Y; Iwanaga, M; Kanamori, H; Kiyoi, H; Maeda, T; Matsuo, K; Miyazaki, Y; Mizuta, S; Monma, F; Naoe, T; Ohtake, S; Sugiura, I; Takeuchi, J; Ueda, Y; Yoshida, C; Yujiri, T	1
Guo, XZ; Guo, YF; Pan, JX; Wu, SX; Zhang, XY	1
Attarbaschi, A; Biondi, A; Bradtke, J; Campbell, M; Cario, G; Castor, A; Conter, V; De Lorenzo, P; Escherich, G; Gandemer, V; Leoni, V; Li, CK; Pieters, R; Saha, V; Schrappe, M; Stary, J; Valsecchi, MG; Vora, A	1
Shu, Y; Xu, X; Yang, W; Zhang, X	1
Bärnthaler, T; Frank, S; Grill, M; Heinemann, A; Jandl, K; Marsche, G; Schicho, R; Schreiber, Y; Schuligoi, R; Sill, H; Thomas, D; Uhl, B	1
Acar, K; Uz, B	1
Baruchel, A; Biondi, A; Bradtke, J; Campbell, M; Cario, G; Castor, A; Cavé, H; Cazzaniga, G; Conter, V; De Lorenzo, P; Escherich, G; Gandemer, V; Grazia Valsecchi, M; Leoni, V; Li, CK; Pieters, R; Saha, V; Schrappe, M; Stary, J; Vora, A	1
Chen, H; Chen, YH; Cheng, YF; Han, W; Huang, XJ; Jia, YP; Liu, KY; Lu, AD; Sun, YQ; Suo, P; Wang, Y; Wu, J; Xu, LP; Xue, YJ; Yan, CH; Zhang, LP; Zuo, YX	1
Leotta, S; Manzella, L; Massimino, M; Milone, G; Pennisi, MS; Puma, A; Romano, C; Sapienza, G; Scalise, L; Stagno, F; Stella, S; Tirrò, E; Vitale, SR	1
Gupta, B; Kumar, A; Pant, G; Pooniya, V; Sharma, A; Verma, N	1
Ayemou, R; Djoko, S; Emeuraude, N; Kamara, I; Koffi, G; Kouakou, B; Meité, N; Nanho, CD; Sanogo, I; Silué, DA; Sowhe, T; Tolo, A	1
Han, J; Hao, J; Jin, R; Qiu, Y; Qu, P; Yu, H; Zhou, F	1
Butt, G; Khokar, A; Malik, U; Naumeri, F	1
Inoue, M; Kawa, K; Kondo, O; Sato, M; Sawada, A; Yamada, K; Yasui, M	1
Cen, JN; Chen, Y; Chen, ZX; Ding, ZX; He, J; Pan, JL; Qiu, QC; Shen, HJ; Yao, L	1
Chen, F; Chen, J; Qiu, HY; Sun, AN; Wu, DP; Zhao, Y	1
Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S	1
Chopra, YR; Ramzan, M; Verma, R; Yadav, SP	1
Buck, G; Fielding, AK; Foroni, L; Gerrard, G; Goldstone, AH; Lazarus, H; Litzow, MR; Luger, SM; Marks, DI; McMillan, AK; Moorman, AV; Paietta, E; Patel, B; Rowe, JM; Tallman, MS	1
Ahmed, W; Van Etten, RA	1
Biondi, A; Cavé, H; Cazzaniga, G; De Lorenzo, P; den Boer, ML; Harrison, CJ; Mottadelli, F; Pieters, R; Saha, V; Schrappe, M; Stanulla, M; Te Kronnie, G; Trka, J; Valsecchi, MG; van der Veer, A; Zaliova, M	1
Marin, D	1
Bhojwani, D; Campana, D; Cheng, C; Choi, JK; Coustan-Smith, E; Howard, SC; Inaba, H; Jacobsen, J; Jeha, S; Metzger, ML; Pei, D; Pui, CH; Raimondi, S; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Shurtleff, SA	1
Bassan, R	1
Hatta, Y	1
Chen, J; Du, S; Hu, J; Li, J; Shen, Z; Wang, A; Wu, W; You, J; Zhou, L	1
Bao, L; Chen, H; Huang, X; Jia, J; Jiang, B; Jiang, H; Jiang, Q; Qin, Y; Wang, J; Yang, S	1
Chen, F; Chen, G; Cheng, Z; Fu, C; Jin, Z; Qiu, H; Sun, A; Tang, X; Wu, D; Xue, S; Zhao, L	1
Davis, A; Gorniak, M; Grigoriadis, G; Ling, VY; Wall, M	1
Feng, S; Han, M; Huang, Y; Jiang, E; Liu, X; Ma, Q; Pang, A; Qiu, L; Wei, J; Yang, D; Zhang, R	1
Cerny-Reiterer, S; Gleixner, KV; Hadzijusufovic, E; Herrmann, H; Jäger, U; Maeda, H; Melo, JV; Meyer, RA; Peter, B; Pickl, WF; Sperr, WR; Stefanzl, G; Valent, P	1
Handa, H; Hatsumi, N; Nojima, Y; Sakura, T; Shimizu, H; Takada, S; Yokohama, A	1
Arthur, C; Boyd, AW; Bradstock, K; D'Rozario, J; Durrant, S; Ellacott, J; Filshie, R; Grigg, A; Hughes, TP; Irving, I; Lickliter, JD; Lynch, K; Rooney, K; Seldon, M; Szer, J; Taylor, K	1
Akhtari, M; Armitage, JO; Bhatt, VR; Bociek, RG; Dave, BJ; Kessinger, A; Sanger, WG; Sanmann, JN; Yuan, J	1
Chen, L; Guérin, A; Hiscock, R; Ionescu-Ittu, R; Keir, C; Marynchenko, M; Nitulescu, R; Wu, EQ	1
Cho, EH; Chung, Y; Eom, HS; Kong, SY; Lee, H; Park, S; Shim, H	1
Sugiura, I	1
Cao, C; Li, X; Liu, T; Shen, K; Zhang, L; Zhu, H	1
Cao, J; Chen, C; Han, ZX; Li, ZY; Lu, XY; Pan, B; Qiao, JL; Song, XG; Wang, L; Wang, M; Wu, QY; Xu, KL; Yan, ZL; Zeng, LY; Zhang, HX; Zhao, K; Zhu, P	1
Chen, XY; Chen, YJ; Zheng, YL	1
Derwich, K; Januszkiewicz-Lewandowska, D; Pieczonka, A; Samborska, M; Skalska-Sadowska, J; Wachowiak, J	1
Brancaccio, M; Camporeale, A; Carrà, G; Crivellaro, S; Cutrin, JC; Di Savino, A; Familiari, U; Ferretti, R; Franco, I; Fusella, F; Gambacorti-Passerini, C; Giugliano, E; Hirsch, E; Miniscalco, B; Morotti, A; Pandolfi, PP; Panuzzo, C; Papotti, M; Piazza, R; Rege-Cambrin, G; Rocca, S; Saglio, G; Silengo, L; Tarone, G; Turco, E	1
Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH	1
Abbal, C; Berthon, C; Cayuela, JM; Chalandon, Y; Chevret, S; Dombret, H; Escoffre-Barbe, M; Hayette, S; Huguet, F; Ifrah, N; Lafage-Pochitaloff, M; Lambert, JF; Leguay, T; Lepretre, S; Lhéritier, V; Maury, S; Raffoux, E; Rousselot, P; Tavernier, E; Thomas, X	1
Boissel, N; Borthakur, G; Brummendorf, TH; Capolongo, L; Carpinelli, P; Cortes, JE; Davite, C; Dombret, H; Jabbour, E; Kantarjian, H; Mariani, M; Schafhausen, P	1
Fukushima, H; Fukushima, T; Kobayashi, C; Nanmoku, T; Sakai, A; Satomi, K; Sumazaki, R; Suzuki, R; Tagawa, M	1
Chen, C; Chen, W; Li, D; Li, Z; Qiu, T; Song, X; Xu, K; Yan, Z; Zeng, L; Zhang, H; Zhang, P	1
Alperstein, W; Boren, M; McNeer, JL	1
Gong, Y; Lin, J; Liu, X; Naren, D; Shi, F; Shi, R; Yan, T; Yang, X	1
Bae, SH; Chi, HS; Eom, HS; Hyun, MS; Jang, DY; Joo, YD; Jung, CW; Kim, DY; Kim, H; Kim, HJ; Kim, I; Kim, MK; Lee, GW; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Lim, SN; Moon, JH; Park, S; Ryoo, HM; Shin, HJ; Sohn, SK; Won, JH; Yang, DH; Yun, SC	1
Chen, XJ; Guo, Y; Liu, F; Liu, TF; Liu, XM; Qi, BQ; Ruan, M; Wang, SC; Yang, WY; Zhang, JY; Zhang, L; Zhu, XF; Zou, Y	1
Gong, Y; Len, Y; Naren, D; Shi, F; Shi, R; Yan, T; Yang, X	1
Altman, JK; Arslan, AD; Beauchamp, EM; Blyth, GT; Curi, DA; Donato, NJ; Giles, FJ; Platanias, LC	1
Akashi, K; Eto, T; Henzan, H; Ito, Y; Kamimura, T; Kato, K; Miyamoto, T; Nagafuji, K; Ohno, Y; Takase, K; Takashima, S; Techima, T; Yoshida, S; Yoshimoto, G	1
Bucelli, C; Cannone, M; Cattaneo, D; Guerneri, S; Iurlo, A; Morotti, D; Zappa, M	1
Cho, DJ; Kim, DW; Kim, SH; Lee, JI; Noh, H; Oh, SJ; Park, HL; Park, MS; Zang, DY	1
Arora, R; Iyer, S; Monif, T; Sharma, M	1
Bozkurt, S; Büyükaşık, Y; Eyüpoğlu, D; Güven, D; Haznedaroğlu, İ	1
Andorsky, D; Assouline, S; Baccarani, M; Chuah, C; Clackson, T; Clark, RE; Cortes, JE; Deininger, MW; Etienne, G; Guerci-Bresler, A; Guilhot, F; Haluska, FG; Hochhaus, A; Hughes, T; Kantarjian, HM; le Coutre, P; Lipton, JH; Lustgarten, S; Nicolini, FE; Oehler, V; Rivera, VM; Rosti, G; Shah, NP; Simpson, D; Stenke, L; Talpaz, M	1
Angelucci, E; Audisio, E; Bassan, R; Borlenghi, E; Boschini, C; Cattaneo, C; Cavattoni, IM; Ciceri, F; Cortelezzi, A; Gianni, F; Grassi, A; Intermesoli, T; Lussana, F; Mannelli, F; Masciulli, A; Mattei, D; Oldani, E; Parolini, M; Raimondi, R; Rambaldi, A; Romani, C; Scattolin, AM; Spinelli, O; Terruzzi, E; Tosi, M	1
Eskazan, AE	1
Andrews, LM; Atiq, F; Broers, AE; Doorduijn, JK; Koch, BC; Van Gelder, T; Versmissen, J	1
Dasappa, L; Jacob, LA; Kanakasetty, GB; Kumari, P; Kuntejowdahalli, L; Mallekavu, SB; Thanky, AH	1
Bhattacharyya, S; Chen, L; Fan, L; Guerin, A; Joseph, G; Li, N; Totev, T; Yang, X	1
Abdulkadyrov, K; Ayala, M; Babu, KG; Bendit, I; Bullorsky, E; Cortes, JE; de Oliveira, JSR; De Souza, CA; Fellague-Chebra, R; Huang, X; Khanna, S; le Coutre, PD; Liang, Z; Lopez, JL; Owugah, T; Sacha, T; Shah, S; Shen, ZX; Szczudlo, T	1
Litzow, MR	1
Asnafi, V; Bastié, JN; Bay, JO; Beldjord, K; Béné, MC; Bernard, M; Charbonnier, A; Chevallier, P; Desjonquères, A; Dombret, H; Himberlin, C; Huguet, F; Hunault, M; Ifrah, N; Isnard, F; Lafage-Pochitaloff, M; Leguay, T; Lepretre, S; Lhéritier, V; Lioure, B; Renaud, M; Tavernier, E; Thomas, X; Turlure, P	1
Benton, CB; Cameron Yin, C; Cortes, JE; Daver, NG; Garcia-Manero, G; Garris, R; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, HM; Khouri, M; Ko, H; Konopleva, M; O'Brien, SM; Patel, K; Ravandi, F; Sasaki, K; Short, NJ; Thomas, D	1
Adachi, S; Hiramatsu, H; Horibe, K; Ishii, E; Kaneko, T; Kato, I; Kato, K; Kato, M; Kawasaki, H; Kodama, Y; Manabe, A; Matsumoto, K; Mizutani, S; Oda, M; Saito, AM; Sano, H; Sato, A; Shimada, H	1
Baccarani, M	1
Gopinath, P; Kamala, LH; Nair, SG; Narayanan, G; Ramachandran, KC; Sreedharan, H; Thambi, SM	1
Goldman, JM; Melo, JV	1
Amabile, M; Arruga, F; Baccarani, M; Baruzzi, A; Berton, G; Chiaretti, S; Cilloni, D; Foà, R; Giannoulia, P; Iacobucci, I; Lonetti, A; Martinelli, G; Messa, F; Ottaviani, E; Pane, F; Paolini, S; Papayannidis, C; Perini, G; Piccaluga, PP; Poerio, A; Saglio, G; Soverini, S; Vitale, A	1
Arima, N; Fujiwara, H; Hamada, H; Matsushita, K; Ozaki, A; Tei, C; Yoshimitsu, M	1
Abou Mourad, YR; Fernandez, HF; Kharfan-Dabaja, MA	1
Duyster, J; Götze, KS; Kancha, RK; Miething, C; Peschel, C; von Bubnoff, N	1
Hino, M; Koh, KR; Nakamae, H; Ohsawa, M; Osugi, H; Sakamoto, E; Sawada, T; Wakasa, K; Yamane, T	1
Baker, KS; Burke, MJ; Luo, X; Trotz, B; Verneris, MR; Wagner, JE; Weisdorf, DJ	1
Aoki, T; Kimura, S; Matsue, K; Odawara, J; Takeuchi, M; Yamakura, M	1
Cho, SG; Han, K; Jung, CK; Kim, CC; Kim, DW; Kim, M; Kim, Y; Lee, S; Lim, J; Min, WS	1
Bruennert, D; Bruns, I; Czibere, A; Gattermann, N; Haas, R; Kronenwett, R; Neumann, F	1
Colombo, D; Finelli, P; Giardino, D; Larizza, L; Malvestiti, F; Perego, D; Rodeschini, O	1
Druker, BJ	1
Boschelli, F; Gambacorti-Passerini, C; Magistroni, V; Marega, M; Perini, P; Piazza, R; Redaelli, S; Rostagno, R	1
Cimino, G; Elia, L; Foà, R; Grammatico, S; Matarazzo, M; Pane, F; Pedace, L; Peluso, AL; Rago, A; Vitale, A	1
Gastl, G; Haun, M; Hoflehner, E; Kircher, B; Nachbaur, D; Petzer, A; Schumacher, P; Wolf, AM	1
Buck, G; Dewald, G; Durrant, IJ; Fielding, AK; Foroni, L; Franklin, IM; Goldstone, AH; Lazarus, HM; Litzow, MR; Luger, SM; Marks, DI; McMillan, AK; Moorman, AV; Paietta, E; Richards, SM; Rowe, JM; Tallman, MS; Wiernik, PH	1
Elmaagacli, AH; Koldehoff, M	1
Ahmed, N; Cang, S; Liu, D; Mathews, T; Primanneni, S; Seiter, K; Tan, J	1
Gruber, F; Mustjoki, S; Porkka, K	1
Doi, Y; Hasegawa, H; Kamihira, S; Matsuo, E; Miyazaki, Y; Mori, S; Nagai, K; Sasaki, D; Terada, C; Tsuruda, K; Yamada, Y; Yanagihara, K	1
Cortes, J; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J	1
Fujiwara, H; Hayama, BY; Iwama, K; Kimura, S; Matsue, K; Matsuo, K; Takeuch, M; Yamakura, M	1
Baccarani, M; Baldazzi, C; Castagnetti, F; Gamberini, C; Luatti, S; Marzocchi, G; Palandri, F; Rosti, G; Stacchini, M; Testoni, N	1
Ottmann, OG; Pfeifer, H	2
Abe, T; Aizawa, Y; Furukawa, T; Kitajima, T; Maruyama, S; Masuko, M; Okada, M; Shibasaki, Y; Toba, K; Wada, R	1
Hackanson, B; Lübbert, M; Rückert, A	1
Abakumov, EM; Aseeva, EA; Chelysheva, EIu; Diachenko, LV; Diagileva, OA; Domracheva, EV; Goriacheva, SR; Gusarova, GA; Ivanova, TV; Khoroshko, ND; Kolosheĭnova, TI; Kolosova, LIu; Kovaleva, LG; Kulikov, SM; Naumova, IN; Semenova, EA; Stakhina, OV; Turkina, AG; Vakhrusheva, MV; Vinogradova, OIu; Vorontsova, AV; Zakharova, AV; Zakharova, ES	1
Goh, HG; Kim, D; Kim, DW; Kim, SH; Kim, WS; Kweon, IY; Lee, J; Park, SH	1
Chen, F; Hou, M; Ji, C; Li, L; Ma, D; Sun, J; Yan, S; Zhang, M	1
Jalkanen, S; Koskenvesa, P; Lundán, T; Mustjoki, S; Porkka, K; Rapakko, K; Rohon, P	1
Bernal, MT; Brunet, S; Bureo, E; de Oteyza, JP; Del Potro, E; Esteve, J; González, M; Martín-Reina, V; Moreno, MJ; Oriol, A; Parody, R; Ribera, JM; Rivas, C; Sarrá, J; Tormo, M; Vidriales, B	1
Aledo, A; Borowitz, MJ; Bowman, WP; Burden, L; Camitta, B; Carroll, A; Carroll, WL; Davies, SM; Devidas, M; Gaynon, PS; Heerema, NA; Hunger, SP; Jorstad, D; Rutledge, R; Sather, H; Schultz, KR; Slayton, WB; Trigg, M; Wang, C; Winick, N	1
Bayrak, A; Besisik, SK; Cefle, K; Diz-Kucukkaya, R; Nalcaci, M; Ozbek, U; Ozturk, S; Palanduz, S; Pekcelen, Y; Sargin, D; Sirma, S; Ucur, A; Vural, B; Yavuz, S; Yenerel, MN	1
Deininger, MW; Druker, BJ; Harrington, CA; Lange, T; Loriaux, MM; MacPartlin, M; McWeeney, SK; Melo, JV; O'Brien, SG; Pemberton, LC; Pillai, R; Snead, JL; Turpaz, Y; Vartanian, K; Willis, SG; Wilmot, B; Yochum, G	1
Mitani, K; Sasaki, K	1
Bommer, C; Daniel, P; Dörken, B; Kim, TD; Koca, G; le Coutre, P; Nogai, H; Schwarz, M; Türkmen, S	1
Enrico, A; Milone, JH	1
Ishii, S; Katayama, Y; Matsui, T; Okamura, A; Wakahashi, K; Yamamoto, K	1
Chen, S; Li, Y; Wang, L; Yang, L; Zha, X; Zhu, K	1
Ahluwalia, MS; Battiwalla, M; Cohen, IL; Francis, J; McCarthy, PL; Paplham, P; Smiley, S; Spangenthal, E; Wang, E; Wetzler, M	1
Chondropoulos, S; Dervenoulas, J; Economopoulos, T; Economopoulou, C; Ionnidou, ED; Konsioti, F; Papageorgiou, E; Papageorgiou, SG; Pappa, V; Tsirigotis, P; Vasilatou, D	1
Arai, A; Kurosu, T; Miura, O; Murakami, N; Oshikawa, G	1
Skorski, T	1
Abe, D; Fujisawa, S; Hoshino, T; Kanamori, H; Kanda, Y; Maruta, A; Nakaseko, C; Nakasone, H; Okamoto, S; Sakura, T; Takahashi, S; Takasaki, H; Usuki, K; Yano, S; Yokota, A	1
Azzena, A; Baccarani, M; Baldazzi, C; Castagnetti, F; Cavazzini, F; Cianciulli, AM; Cipriani, R; Dalsass, A; Donti, E; Gamberini, C; Giannini, B; Giugliano, E; Gozzetti, A; Grimoldi, MG; Luatti, S; Marzocchi, G; Ronconi, S; Rosti, G; Santoro, A; Spedicato, F; Stacchini, M; Testoni, N; Tonelli, M; Valenti, AM; Zaccaria, A; Zanatta, L	1
Alcalá, M; Barrios, M; Heiniger, AI; Jiménez-Velasco, A	1
Barr, RD	1
Chen, XC; Li, CX; Liu, H; Liu, YJ; Ma, X; Sun, DP; Wu, DP; Wu, XJ	1
Goto, H; Hara, Y; Kamura, Y; Mugishima, H; Oikawa, A; Shichino, H	1
Kilara, N; Manjunath, R; Mysorekar, V; Subramanian, M	1
Alvarez-Calderon, F; Degregori, J; Druker, BJ; Eide, CA; Gregory, MA; Neviani, P; O'Hare, T; Perrotti, D; Phang, TL; Williams, RT; Zaberezhnyy, V	1
Fielding, AK	1
Arnold, R; Braun, D; Dörken, B; Grille, P; Kim, TD; le Coutre, P; Nogai, H; Plöckinger, U; Schwarz, M; Schweizer, U; Westermann, J	1
Cojbasić, I; Macukanović-Golubović, L	2
Chen, Y; Li, D; Li, S; Peng, C	1
Alfonso, G; Alú, MF; Belli, C; Bianchini, M; Larripa, I	1
Fujimori, Y; Ikegame, K; Kaida, K; Ogawa, H; Okada, M; Satake, A; Soma, T; Tamaki, H; Taniguchi, K; Yoshihara, S	1
Chang, H; Gong, YP; Xing, HY; Yang, L; Yang, X; Zheng, BH; Zhou, RQ	1
Kawasaki, Y; Nakazora, T; Shinohara, K; Suzukawa, M; Tominaga, T	1
Dan, K; Hamada, Y; Nakamura, K; Tajika, K	1
Hashidate, H; Nikkuni, K; Shibuya, H; Takai, K; Ushiki, T	1
Amabile, M; Baccarani, M; Baldazzi, C; Bonaldi, L; Castagnetti, F; Cianciulli, AM; Discepoli, G; Giacobbi, F; Giudici, G; Giussani, U; Gugliotta, G; Luatti, S; Martinelli, G; Marzocchi, G; Montaldi, A; Palandri, F; Pane, F; Rosti, G; Saglio, G; Santoro, A; Sessarego, M; Specchia, G; Stacchini, M; Testoni, N; Valori, L	1
Ben Youssef, Y; Bennour, A; Elloumi, M; Harrabi, I; Khelif, A; Laatiri, MA; Meddeb, B; Ouahchi, I; Saad, A; Sennana, H; Zaier, M	1
Alimena, G; Breccia, M; Cannella, L; De Cuia, R; Federico, V; Loglisci, G; Loglisci, MG; Mancini, M; Nanni, M; Salaroli, A; Santopietro, M; Serrao, A	1
Akahane, K; Goi, K; Hirose, K; Honna, H; Inukai, T; Kagami, K; Kuroda, I; Sugita, K; Tauchi, T; Yagita, H; Zhang, X	1
Chandra, HS; Heisterkamp, NC; Hungerford, A; Morrissette, JJ; Nowell, PC; Rowley, JD; Testa, JR	1
Cortes, J; Kantarjian, H; Mathisen, MS; O'Brien, S; Ravandi, F; Thomas, D	1
Badell, I; Couselo, JM; de Miguel, PG; Estella, J; Fernández-Delgado, R; Fernández-Teijeiro, A; Gómez, P; Lendínez, F; López-Almaraz, R; López-Duarte, M; López-Ibor, B; Maldonado, M; Melo, M; Moreno, MJ; Rives, S; Rodríguez, I; Tasso, M; Uriz, J; Verdeguer, A; Vivanco, JL	1
Branford, S; Buonomo, T; Colavita, I; Del Vecchio, L; Esposito, N; Hughes, TP; Kalebic, T; Luciano, L; Martinelli, G; Martinelli, R; Melo, JV; Pane, F; Peluso, AL; Picardi, M; Quintarelli, C; Radich, JP; Ruoppolo, M; Russo, D; Saglio, G; Sica, AR; White, D	1
Alimena, G; Breccia, M; Cannella, L; Colafigli, G; De Cuia, MR; Loglisci, G; Nanni, M; Salaroli, A; Serrao, A	1
Blakesley, RE; De Souza, C; Flinn, IW; Gallagher, NJ; Goh, YT; Hochhaus, A; Hoenekopp, A; Hughes, TP; Kantarjian, HM; Larson, RA; Nakamae, H; Rosti, G; Saglio, G; Stenke, L	1
Davies, J	1
Chan, KW; Lockhart, S; McDonald, L; Rytting, M	1
Angelopoulou, MK; Bartzi, V; Bitsani, A; Boutsikas, G; Dimou, M; Efthymiou, A; Georgiou, G; Kyrtsonis, MC; Panayiotidis, P; Pessach, I; Plata, E; Tofas, P; Vardounioti, I; Vassilakopoulos, TP	1
Balduzzi, A; Berger, M; Fagioli, F; Favre, C; Lanino, E; Lo Nigro, L; Locatelli, F; Masetti, R; Messina, C; Prete, A; Rabusin, M; Rognoni, C; Zecca, M	1
DeAngelo, DJ	1
Chosa, N; Fukudome, T; Hisakata, T; Horikawa, N; Ito, M; Kanda, Y; Kawano, N; Kugimiya, H; Okuda, S; Sakurai, R; Ueda, A; Yamashita, K; Yoshida, S	1
Binckebanck, A; Brück, P; Dührsen, U; Giagounidis, A; Hoelzer, D; Lange, T; Maier, J; Ottmann, OG; Pfeifer, H; Schmalzing, M; Schmidt, A; Serve, H; Stelljes, M; Wassmann, B; Wunderle, L; Wystub, S	1
Allan, DS; Huang, H; Luo, Y; Sun, J; Tan, Y; Wang, Z	1
Cantú-Rodríguez, O; García-Rodríguez, F; Gómez-Almaguer, D; González-Llano, O; Gutiérrez-Aguirre, H; Jaime-Pérez, J	1
Anagnostopoulos, A; Athanasiadou, A; Batsis, I; Gaitatzi, M; Papaioannou, G; Touloumenidou, T; Voutiadou, G	1
Camitta, BM; Carroll, WL; Chang, BH; Druker, BJ; Hunger, SP; Schultz, KR; Stork, L; Willis, SG; Winick, NJ	1
Bennett, C; Cornfield, D; Cross, N; Shah, U; Sun, G	1
Chen, ZM; Jin, J; Lou, JY; Meng, HT; Ni, WM; Qian, WB; Tong, HY; Wang, YG; Zhang, YF	1
Atallah, E; Haddad, RY; Torgerson, SR	1
Candrilli, SD; Iyer, S; Kaye, JA; Mitra, D; Trask, PC	1
Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C	1
Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Liu, YR; Qin, YZ; Wang, Y; Xu, LP; Zhang, XH; Zhang, YY; Zhao, XY	1
Abruzzese, E; Ameli, G; Baccarani, M; Baldazzi, C; Bernasconi, P; Cambrin, R; Capucci, MA; Castagnetti, F; Gozzetti, A; Grimoldi, MG; Gugliotta, G; Iacobucci, I; Luatti, S; Mancini, M; Martinelli, G; Marzocchi, G; Palandri, F; Palka, G; Pane, F; Rege-Cambrin, G; Rosti, G; Saglio, G; Specchia, G; Testoni, N; Zaccaria, A; Zanatta, L	1
Bracci, PM; Broderick, P; Call, TG; Camp, NJ; Caporaso, NE; Catovsky, D; Cerhan, JR; Conde, L; Croft, N; Cunningham, JM; Dearden, C; Di Bernardo, MC; Dyer, MJ; Goldin, LR; Halperin, E; Harris, S; Holroyd, A; Houlston, RS; Kay, NE; Lanasa, MC; Leis, JF; Matutes, E; McDonnell, SK; Morrison, VA; Riby, J; Serie, DJ; Shanafelt, TD; Skibola, CF; Slager, SL; Spector, LG; Strom, SS; Vachon, CM; Wade, R; Weinberg, JB	1
Cho, BS; Chung, NG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH	1
Dingermann, T; Marschalek, R; Zündorf, I	1
Aricò, M; Biondi, A; Campbell, M; Castor, A; De Lorenzo, P; Escherich, G; Gandemer, V; Li, CK; Lucchini, G; Pieters, R; Röttgers, S; Saha, V; Schrappe, M; Stary, J; Valsecchi, MG; Vora, A	1
Thomas, D	1
Cahn, JY; Cayuela, JM; Chalandon, Y; Delannoy, A; Dombret, H; Escoffre, M; Hayette, S; Huguet, F; Ifrah, N; Réa, D; Rousselot, P; Tanguy-Schmidt, A; Thomas, X; Vekemans, MC; Vernant, JP	1
Bhatt, S; de Figueiredo, AF; de Souza, MT; Liehr, T; Ney-Garcia, DR; Ribeiro, RC; Silva, ML; Vieira, TP	1
Chen, SN; Dai, HP; Gong, YL; Pan, JL; Wu, DP; Wu, LL; Wu, YF; Xue, YQ; Zhang, J	1
Capra, ME; Fogliatto, LM; Koshiyama, DB; Oliveira, CA; Paskulin, GA; Rosa, RF; Vanelli, T; Zen, PR	1
Akahane, K; Fujimoto, J; Goi, K; Hirose, K; Honna-Oshiro, H; Inaba, T; Inukai, T; Kagami, K; Kiyokawa, N; Miyagawa, Y; Nakazawa, S; Nemoto, A; Sato, H; Sugita, K; Takahashi, K; Uno, K	1
Alimena, G; Barulli, S; Breccia, M; Carmosino, I; Diverio, D; Federico, V; Finsinger, P; Isidori, A; Latagliata, R; Loglisci, G; Mancini, M; Nanni, M; Santopietro, M; Visani, G; Volpicelli, P; Vozella, F	1
Kurosu, T; Miura, O; Nagao, T; Oshikawa, G; Wu, N	1
Fan, ZP; Huang, F; Jiang, QL; Ling, YW; Liu, QF; Sun, J; Zhai, X; Zhang, FH; Zhang, Y; Zhou, HS	1
Arlinghaus, R; Atallah, E; Fernandes-Reese, S; Guo, JQ; Kantarjian, H; O'brien, S; Rios, MB; Talpaz, M	1
Beran, M; Dong, L; Kantarjian, HM; Keating, MJ; Onida, F; Scappini, B; Verstovsek, S	1
Balleisen, S; Capdeville, R; Druker, BJ; Kurilik, G; Magenis, E; Mauro, MJ; Mori, M; O'Dwyer, ME; Olson, S	1
Clark, RE; Ferguson, JE; Pearson, K; Pillitteri, L; Wang, L	1
Al-Ali, HK; Bumm, T; Deininger, MW; Franke, C; Friedrich, T; Hennig, E; Krahl, R; Krohn, K; Leiblein, S; Müller, C; Niederwieser, D; Schmidt, E; Shepherd, P	1
Goldman, JM; Lagarde, V; Mahon, FX; Melo, JV; Tipping, AJ; Zafirides, G	1
Clark, RE; Lin, K; Salim, R; Wang, L	1
Drummond, MW; Holyoake, TL; Kaeda, J; Lush, CJ; Reid, FM; Vickers, MA	1
Demuynck, H; Hagemeijer, A; Martiat, P; Meeus, P; Michaux, L; Wouters, E	1
Apperley, JF; Bua, M; Foot, N; Goldman, JM; Marin, D; Marktel, S	1
Bernu S, T; Besalduch, J; Guti Rrez, A; Parody, R	1
Belinchon-Romero, I; Fernandez-Abellan, P; Pascual-Ramirez, JC; Rivas, C; Sanchez-Gonzalez, B; Vegara-Aguilera, G	1
Hoelzer, D; Ottmann, OG; Wassmann, B	1
Campbell, L; Grigg, A; Hoyt, R; Juneja, S; Lynch, K; McNamara, C; Roberts, A; Szer, J	1
Braziel, RM; Druker, BJ; Gatter, KM; Lawce, H; Loriaux, M; Magenis, RE; Mauro, MJ; Maziarz, RT; O'Dwyer, ME; Olson, SB	1
Chee, YL; Culligan, DJ; Holyoake, TL; Stevenson, D; Vickers, MA	1
Abgrall, JF; Berthou, C; Braekeleer, MD; Bris, MJ; Calvez, GL; Herry, A; Marion, V; Morel, F	1
Drechsler, M; Haas, R; Herold, C; Hildebrandt, B; Kronenwett, R; Redmann, A; Royer-Pokora, B; Wieland, C	1
Branford, S; Goh, KY; Grigg, A; Hoyt, R; Hughes, TP; Hui, CH; Kwan, YL; Ma, DD; Rudzki, B; Seymour, JF; To, LB; Trickett, A; Walsh, S; White, D	1
Druker, BJ; Kantarjian, HM; Kurzrock, R; Talpaz, M	1
Brandt, H; Mohamed, AN; Pemberton, P; Schiffer, CA; Zonder, JA	1
Ono, R	1
Chiba, H; Hirayama, Y; Kato, J; Maeda, M; Matsunaga, T; Niitsu, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y	1
Oehler, VG; Radich, JP	1
Chadburn, A; Feldman, E; Najfeld, V; Roboz, G; Schuster, M; Silver, RT	1
Huang, F; Liu, XL; Meng, FY; Song, LL; Xu, B; Zhang, Y; Zheng, WY	1
Antin, JH	1
Dan, K; Inami, M; Inokuchi, K; Nakayama, K; Shimada, T; Tamura, H	1
Blaise, D; Caillères, S; Lafage-Pochitaloff, M; Maurice, C; Mozziconacci, MJ; Sainty, D; Vey, N	1
Byrne, J; Cuthbert, RJ; Humphreys, M; McMullin, MF; O'Dwyer, ME; Russell, NH	1
Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S	1
Cherrier-De Wilde, S; Delannoy, A; Hagemeijer, A; Rack, K; Vannuffel, P	1
Beissert, T; Güller, S; Hoelzer, D; Li, JE; Ottmann, OG; Puccetti, E; Ruthardt, M	1
Jin Huh, H; Lee, M; Myong Seong, C; Soon Chung, W; Won Huh, J	1
Byrne, JL; Clark, RE; Drummond, MW; Holyoake, TL; Lennard, A; Marin, D	1
Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, M; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S; Wierda, W	1
Kolb, EA; Ladanyi, M; Pan, Q; Steinherz, PG	1
Liu, QF; Liu, XL; Meng, FY; Song, LL; Sun, J; Xu, B; Xu, D; Yang, LJ; Zhou, SY	1
Aggarwal, BB; Albitar, M; Arlinghaus, R; Donato, NJ; Hayes, K; Kantarjian, H; Lin, H; Shishodia, S; Shishodin, S; Stapley, J; Talpaz, M; Wu, JY	1
Al-Ali, HK; Bumm, T; Deininger, MW; Köhler, T; Kovacs, I; Krahl, R; Krug, D; Lange, T; Niederwieser, D; Otto, S	1
Hino, N; Myojo, T	1
Usui, N	2
Anagnostopoulos, A; Asteriou, O; Athanasiadou, A; Fassas, A; Saloum, R; Stavroyianni, N	1
Gumerlock, PH; Hatcher, S; Larkin, E; Richman, C; Rodler, E; Unger, K; Welborn, J; Wun, T	1
Adil, SN; Arain, S; Kakepoto, GN; Khurshid, M; Sajid, R; Usman, M	1
Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Letvak, L; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D; Verstovsek, S	1
Cortes, J; Kantarjian, H	1
Asano, S; Bai, Y; Chen, M; Harata, M; Iseki, T; Izawa, K; Kobayashi, S; Maruyama, K; Nagamura, F; Nakazawa, S; Ooi, J; Soda, Y; Sugita, K; Takahashi, S; Takahashi, TA; Takizawa, T; Tani, K; Tojo, A; Tomonari, A; Tsuji, T; Uchimaru, K	1
Cortes, JE; Faderl, S; Garcia-Manero, G; Giles, F; Jones, D; Kantarjian, HM; Luthra, R; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D; Verstovsek, S	1
Bernstein, M; Blaney, SM; Capdeville, R; Champagne, MA; Krailo, M; Peng, B; Qu, W; Rosamilia, M; Therrien, M; Zoellner, U	1
Goldman, JM; Mughal, TI	2
Bando, S; Fujita, S; Hato, T; Hojo, N; Kohno, M; Niiya, Y; Sakai, I; Takada, K; Tamura, T; Yakushijin, Y; Yamanouchi, J; Yasukawa, M	1
Agis, H; Geissler, K; Haas, OA; Kalhs, P; Keil, F; Krauth, MT; Lechner, K; Mannhalter, C; Pirc-Danoewinata, H; Sperr, WR; Valent, P	1
Abakumov, EM; Domracheva, EV; Khoroshko, ND; Nemchenko, IS; Semenova, EA; Sokolova, MA; Turkina, AG; Vinogradova, OIu; Zakharova, AV	1
Goldman, J	1
Klepfish, A; Patchenko, P; Rachmilewitz, EA; Rothman, R; Trakhtenbrot, L	1
Popat, U; Rice, L	1
Bork, S; Brors, B; Eils, R; Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Kliszewski, S; Kronenwett, R; Neumann, F; Roes, N; Royer-Pokora, B; Schimkus, N; Steidl, U; Teutsch, N	1
Bessho, F; Hayashi, Y; Hongo, T; Ida, K; Kawaguchi, H; Kobayashi, M; Koh, K; Park, MJ; Taketani, T; Taki, T; Takita, J; Yoshino, H	1
Bacher, U; Berger, U; Haferlach, T; Hehlmann, R; Hiddemann, W; Hochhaus, A; Schoch, C	1
Czepulkowski, B; Jan-Mohamed, R; Kaczmarski, R; Pavlu, J	1
Campbell, PJ; Curtin, NJ; Green, AR	1
Cortes, J; Dewald, GW; Kantarjian, HM; Litzow, ML; Mauro, MJ; Talpaz, M; Tefferi, A	1
Duch-Samper, A; Hurtado-Sarrió, M; Martínez-Dominguez, JA; Menezo-Rozalén, JL; Senent-Peris, ML; Taboada-Esteve, J	1
Huang, Q	1
Eckhardt, S	1
Aleskog, A; Barbany, G; Björnberg, A; Hallböök, H; Larsson, R; Lindhagen, E; Sundström, C	1
Chen, SS; Jiang, B; Jiang, H; Jiang, Q; Lu, DP; Lu, Y; Qiu, JY	1
Gordon, MY; Marley, SB	1
Chatterjee, T; Choudhry, DR; Choudhry, VP; Dixit, A; Kumar, R; Mahapatra, M; Mishra, P; Sazawal, S; Tyagi, S	1
Fay, M; Goldman, J; Murphy, PT; O'Donnell, R; Quinn, J; Swords, R	1
Barrett, AJ; Childs, RW; Dorrance, C; Espinoza-Delgado, I; Igarashi, T; Lundqvist, A; Rezvani, K; Savani, BN; Srinivasan, R; Takahashi, Y	1
D'Antonio, J	1
Aksu, S; Cetiner, D; Goker, H; Haznedaroglu, IC; Koca, E; Ozcebe, OI; Turgan, C	1
Chiusolo, P; De Matteis, S; De Vita, S; Fiorini, A; Laurenti, L; Leone, G; Piccirillo, N; Reddiconto, G; Sica, S; Sorà, F	1
Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B	1
Ottmann, OG; Wassmann, B	1
Bernheim, A; Bories, D; Bourhis, JH; Brouzes, C; Clausse, B; Danglot, G; Fauvet, D; Leon, B; Lozach, F; Ossard-Receveur, A; Turhan, AG	1
Ault, P; Beran, M; Cortes, J; Faderl, S; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Rios, MB; Talpaz, M	1
Connor, RF; Hurd, D; Koty, P; Molnár, I; Pettenati, MJ	1
Ishii, Y; Kimura, Y; Ohyashiki, K; Shoji, N	1
Appelbaum, F; Apperley, J; Baccarani, M; Cervantes, F; Cortes, J; Deininger, M; Goldman, J; Gratwohl, A; Guilhot, F; Hehlmann, R; Hochhaus, A; Horowitz, M; Hughes, T; Kantarjian, H; Larson, R; Niederwieser, D; Saglio, G; Silver, R; Simonsson, B	1
Naithani, R; Panigrahi, I	1
Béné, MC; Berthaud, P; Bilhou-Nabera, C; Bologna, S; Buzyn, A; Caillères, S; Castaigne, S; Coso, D; Darre, S; Delabesse, E; Delain, M; Delannoy, A; Dombret, H; Dubruille, V; Fohrer, C; Garban, F; Isnard, F; Legrand, O; Lhéritier, V; Raby, P; Raffoux, E; Reman, O; Rigal-Huguet, F; Sonet, A; Thomas, X; Turlure, P	1
Urabe, A	1
Bassetti, A; Bianchi, E; Donti, E; Giannini, B; Liberati, AM; Prontera, P; Saglio, G; Valenti, A; Venti, G; Zaccaria, A	1
Baccarani, M; Cilloni, D; Iacobucci, I; Martinelli, G; Pane, F; Saglio, G; Soverini, S	1
Chan, LC; Liu, HS; So, CC; Wan, TS; Wong, ML; Yip, SF	1
Buzyn, A; Cayuela, JM; Chalandon, Y; de Labarthe, A; Delabesse, E; Dombret, H; Escoffre, M; Huguet-Rigal, F; Ifrah, N; Lhéritier, V; MacIntyre, E; Maury, S; Pigneux, A; Réa, D; Reman, O; Rousselot, P; Thomas, X; Vekemans, MC; Vernant, JP; Witz, F	1
Handa, H; Irisawa, H; Iriuchishima, H; Karasawa, M; Matsushima, T; Murakami, H; Nojima, Y; Saitoh, T; Tsukamoto, N; Yamane, A	1
Benson, RE; Farthing, PM; Loescher, AR; North, S; Payne, M; Rodd, HD	1
Chun, K; Kamel-Reid, S; Lipton, J; Medeiros, BC	1
Kimura, S	1
Brothman, AR; Chen, Z; Gaffney, MR; Nibley, WE; Rowe, LR	1
Eaves, A; Eaves, C; Jiang, X; Smith, C	1
Ault, P	1
Konopka, L; Kos, K; Majewski, M; Pastwińska, A; Pienkowska-Grela, B; Solarska, I; Woroniecka, R	1
Asmus, C; Iqbal, MA; Lee, A; Li, L; Liesveld, JL; O'Malley, J; Siebert, S; Szych, CM; Wang, N	1
Katayama, N; Nishii, K; Ryuu, H; Sakakura, M; Tsukada, T	1
Cheung, K; Kamel-Reid, S; Lipton, JH; Ostro, D	1
Baccarani, M; Iacobucci, I; Martinelli, G; Soverini, S	1
Donti, E; Gozzetti, A; Ronconi, S; Spedicato, F; Valenti, AM; Zaccaria, A	1
Erben, P; Fabarius, A; Frank, O; Giehl, M; Haferlach, C; Hehlmann, R; Hochhaus, A; Lahaye, T; Müller, MC; Seifarth, W	1
Beelen, DW; Elmaagacli, AH; Koldehoff, M; Steckel, NK	1
Druker, BJ; Sherbenou, DW	1
Martinelli, G; Paolini, S; Piccaluga, PP	1
Barbu, V; Bories, D; Coppo, P; Gorin, NC; Portnoï, MF; Van Den Akker, J	1
Oestreicher, P	1
Chen, F; Hou, M; Ji, C; Li, L; Sun, J; Wang, W; Yan, S; Zhang, C; Zhang, M	1
Alimena, G; Breccia, M; Cannella, L; Nanni, M; Stefanizzi, C	1
Baccarani, M; Martinelli, G; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G	1
Dewald, GW; Ketterling, RP; Knudson, RA; Landstrom, AP; Tefferi, A	1
Ashihara, E; Kimura, S; Maekawa, T	1
Chen, SS; Huang, XJ; Jiang, B; Jiang, Q; Qiu, JY; Zhang, Y	1
Thomas, DA	1
Cross, SA; Lyseng-Williamson, KA	1
Wassmann, B	1
Swords, R	1
Brandwein, J	1
Hochhaus, A	1
Kim, PS; Lee, PP; Levy, D	1
Beth Rios, M; Cortes, J; Faderl, S; Garcia-Manero, G; Huang, X; Kantarjian, H; O'Brien, S; Ravandi-Kashani, F; Shan, J; Verstovsek, S	1
Allan, EK; Copland, M; Hamilton, A; Holyoake, TL; Lee, FY; Pellicano, F; Richmond, L; Weinmann, R	1
Steinberg, M	1
Andersson, A; Fioretos, T; Gullberg, U; Håkansson, P; Lassen, C; Nilsson, B	1
Ichikawa, N; Kobayashi, H; Shimizu, I; Sumi, M; Ueno, M; Yotsumoto, M	1
Akiyama, H; Jinnai, I; Maruta, A; Matsuo, K; Miyawaki, S; Miyazaki, Y; Naoe, T; Narimatsu, H; Nishii, K; Ohno, R; Ohtake, S; Sugiura, I; Takeuchi, J; Takeuchi, M; Ueda, Y; Usui, N; Yagasaki, F; Yanada, M	1
Liu, XL; Zhang, S; Zhu, HQ	1
Dombret, H; Thomas, X	1
Kranz, S; Mohren, M; Neum, S; Schalk, E; Scheinpflug, K	1
Buttignol, S; Candoni, A; Fanin, R; Simeone, E; Sperotto, A; Tiribelli, M	1
Chen, ZC; Li, QB; Li, WM; You, Y; Zhu, XM; Zou, P	1
Arlinghaus, RB; Beran, M; Cao, X; Estrov, Z; Jeha, S; Jin, G; Kantarjian, H; Lydon, NB; O'Brien, S; Talpaz, M	1
Deininger, MW; Goldman, JM; Gora-Tybor, J; Melo, JV	1
Dan, S; Naito, M; Tsuruo, T	1
Algate, PA; Byrne, CH; Griffin, JD; Rohrschneider, LR; Sattler, M; Shrikhande, G; Verma, S; Winkler, T	1
Druker, BJ; Mauro, MJ	1
Capdeville, R; Druker, BJ; Ford, JM; Kantarjian, H; Reese, SF; Resta, DJ; Sawyers, CL; Talpaz, M	1
de Boer, J	1
Holyoake, DT	1
Griffin, JD; Sattler, M	1
Ellwood, K; Gorre, ME; Hsu, N; Mohammed, M; Paquette, R; Rao, PN; Sawyers, CL	1
Etienne, G; Mahon, FX	1
Guilhot, F	1
Neylon, A; O'Brien, S	1
Davidson, RJ; Eades, A; Goldman, JM; Gordon, MY; Lewis, JL; Marley, SB; Nguyen, DX; Parker, S	1
Mahon, FX	1
Jeanteur, P	1
Najfeld, V; Silver, RT; Sirulink, A	1
Jinnai, I	1
Baccarani, M; Brown, R; Capdeville, R; Cony-Makhoul, P; Druker, B; Facon, T; Fischer, T; Gambacorti-Passerini, C; Goldman, J; Gratwohl, A; Guilhot, F; Hochhaus, A; Kantarjian, H; Lazzarino, M; Loughran, T; Mandelli, F; Miller, C; Morra, E; Niederwieser, D; O'Brien, SG; Ottmann, O; Resta, D; Russell, N; Russo, D; Saglio, G; Sawyers, C; Schiffer, C; Schuster, M; Stone, R; Tallman, M; Talpaz, M; Zoellner, U	1
Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Resta, D; Rios, MB; Shan, J; Talpaz, M; Thomas, DA	1
Braziel, RM; Druker, BJ; Launder, TM; Magenis, RE; Mauro, MJ; O'Dwyer, ME; Olson, SB; Paquette, RL; Sawyers, CL	1
Andersen, MK; Brøndum-Nielsen, K; Dufva, IH; Kjeldsen, L; Pedersen-Bjergaard, J	1
Bär, C; Debatin, KM; Hecker, S; Reinhardt, D; Schmidt-Rohr, U; Selle, B; Viehmann, S	1

Reviews

71 review(s) available for imatinib mesylate and Ph 1 Chromosome

Article	Year
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia. Pharmacological research, 2022, Volume: 178 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors	2022
Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. JAMA oncology, 2022, 09-01, Volume: 8, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2022
De nove Philadelphia chromosome-positive myelodysplastic syndromes with complex karyotype and p230 Hematology (Amsterdam, Netherlands), 2023, Volume: 28, Issue:1 Topics: Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Philadelphia Chromosome	2023
Control of Ph Medical oncology (Northwood, London, England), 2023, Jul-13, Volume: 40, Issue:8 Topics: Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors	2023
Use of tyrosine kinase inhibitors for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia: a systematic review and meta-analysis. BMJ open, 2021, 01-19, Volume: 11, Issue:1 Topics: Child; Disease-Free Survival; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic	2021
Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best practice & research. Clinical haematology, 2017, Volume: 30, Issue:3 Topics: Antineoplastic Agents; Dasatinib; Disease Management; Fusion Proteins, bcr-abl; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Mutation; Philadelphia Chromosome; Precision Medicine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Survival Analysis; Transplantation, Homologous	2017
How is the Ph-like signature being incorporated into ALL therapy? Best practice & research. Clinical haematology, 2017, Volume: 30, Issue:3 Topics: Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Janus Kinases; Molecular Targeted Therapy; Nitriles; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; STAT Transcription Factors; Survival Analysis; Transplantation, Homologous	2017
Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review. Annals of hematology, 2018, Volume: 97, Issue:6 Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome	2018
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology. American Society of Hematology. Education Program, 2013, Volume: 2013 Topics: Australia; Benzamides; Clinical Trials as Topic; Disease-Free Survival; France; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate	2013
Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-10, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Arterial Occlusive Diseases; Asthenia; Benzamides; Bone Marrow Examination; Cytogenetic Analysis; Drug Administration Schedule; Drug Substitution; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Phenotype; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome	2014
[Acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Humans; Imatinib Mesylate; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Young Adult	2014
[Current treatment of philadelphia chromosome-positive acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Molecular Typing; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Young Adult	2014
Should anyone with Philadelphia chromosome-positive ALL who is negative for minimal residual disease receive a hematopoietic stem cell transplant in first remission? Best practice & research. Clinical haematology, 2016, Volume: 29, Issue:4 Topics: Allografts; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2016
Isodicentric Philadelphia Chromosome: A Rare Chromosomal Aberration in Imatinib-Resistant Chronic Myelogenous Leukemia Patients - Case Report with Review of the Literature. Cytogenetic and genome research, 2016, Volume: 150, Issue:3-4 Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome	2016
BCR-ABL in chronic myelogenous leukemia--how does it work? Acta haematologica, 2008, Volume: 119, Issue:4 Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2008
Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:9 Topics: Adult; Algorithms; Benzamides; Disease-Free Survival; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Survival Rate; Transplantation, Homologous	2008
Translation of the Philadelphia chromosome into therapy for CML. Blood, 2008, Dec-15, Volume: 112, Issue:13 Topics: Benzamides; Biomedical Research; Drug Delivery Systems; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2008
t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis. Cancer investigation, 2009, Volume: 27, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 9; Cyclophosphamide; Dasatinib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Thiazoles; Translocation, Genetic; Vincristine	2009
Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. British journal of haematology, 2009, Volume: 145, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Combined Modality Therapy; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation Conditioning; Treatment Outcome	2009
First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Current opinion in oncology, 2009, Volume: 21 Suppl 1 Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Dasatinib; Humans; Imatinib Mesylate; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Treatment Outcome	2009
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML). European journal of haematology, 2009, Dec-01, Volume: 83, Issue:6 Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytosis; Male; Monosomy; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic	2009
[Molecular pathogenesis of chronic myeloid leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10 Topics: Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Gene Silencing; Gene Targeting; Genes, Tumor Suppressor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction	2009
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia & lymphoma, 2009, Volume: 50 Suppl 2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Child; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines	2009
Genomic instability: The cause and effect of BCR/ABL tyrosine kinase. Current hematologic malignancy reports, 2007, Volume: 2, Issue:2 Topics: Apoptosis; Benzamides; Cell Differentiation; Disease Progression; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Genetic; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species	2007
Imatinib mesylate in children and adolescents with cancer. Pediatric blood & cancer, 2010, Jul-15, Volume: 55, Issue:1 Topics: Adolescent; Benzamides; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2010
Molecular and cellular bases of chronic myeloid leukemia. Protein & cell, 2010, Volume: 1, Issue:2 Topics: 5-Lipoxygenase-Activating Proteins; Animals; Benzamides; Disease Models, Animal; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyrimidines	2010
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Current hematologic malignancy reports, 2011, Volume: 6, Issue:3 Topics: Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous	2011
Chronic myelogenous leukemia for primary care physicians. Disease-a-month : DM, 2012, Volume: 58, Issue:4 Topics: Benzamides; Biopsy, Fine-Needle; Bone Marrow; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Philadelphia Chromosome; Piperazines; Platelet Count; Pregnancy; Pregnancy Complications, Neoplastic; Primary Health Care; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic	2012
[Leukemia: A highly malignant disease]. Pharmazie in unserer Zeit, 2012, Volume: 41, Issue:3 Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Disease Models, Animal; History, 19th Century; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Tretinoin	2012
Imatinib for relapsed BCR/ABL positive leukemias. Annals of hematology, 2002, Volume: 81 Suppl 2 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Stem Cell Transplantation	2002
Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment. Leukemia, 2003, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 2; Clinical Trials, Phase III as Topic; Clone Cells; Disease Progression; DNA-Binding Proteins; Enzyme Inhibitors; Follow-Up Studies; Fusion Proteins, bcr-abl; Histone-Lysine N-Methyltransferase; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Myeloid-Lymphoid Leukemia Protein; Philadelphia Chromosome; Piperazines; Proto-Oncogenes; Pyrimidines; Randomized Controlled Trials as Topic; Transcription Factors; Translocation, Genetic	2003
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Annals of internal medicine, 2003, May-20, Volume: 138, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Genes, abl; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Animal; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic	2003
[Molecular targeting therapy for chronic myelogenous leukemia]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, May-10, Volume: 92, Issue:5 Topics: Animals; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fusion Proteins, bcr-abl; Gene Targeting; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2003
Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia. Current oncology reports, 2003, Volume: 5, Issue:5 Topics: Benzamides; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence	2003
Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission. Leukemia, 2003, Volume: 17, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2003
Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome. American journal of hematology, 2003, Volume: 74, Issue:3 Topics: Benzamides; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction	2003
Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer, 2003, Dec-15, Volume: 98, Issue:12 Topics: Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Philadelphia Chromosome; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Survival Rate; Treatment Outcome	2003
[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia]. Rinsho byori. The Japanese journal of clinical pathology, 2004, Volume: 52, Issue:2 Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic	2004
Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature. American journal of hematology, 2004, Volume: 75, Issue:4 Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Mantle-Cell; Male; Philadelphia Chromosome; Piperazines; Pyrimidines	2004
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer, 2004, May-15, Volume: 100, Issue:10 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Myeloproliferative Disorders; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2004
Chronic myeloid leukemia: current status and controversies. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:7 Topics: Benzamides; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Selection; Philadelphia Chromosome; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation	2004
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clinic proceedings, 2005, Volume: 80, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Treatment Outcome	2005
[Imatinib therapy for patients with chronic myelogenous leukemia]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3 Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction	2005
[Clinical studies with imatinib in 2004]. Orvosi hetilap, 2005, May-01, Volume: 146, Issue:18 Suppl 1 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dermatofibrosarcoma; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2005
Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clinical science (London, England : 1979), 2005, Volume: 109, Issue:1 Topics: Benzamides; Cell Proliferation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Translocation, Genetic	2005
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era. Frontiers in bioscience : a journal and virtual library, 2006, Jan-01, Volume: 11 Topics: Animals; Antineoplastic Agents; Benzamides; Cancer Vaccines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Models, Genetic; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction	2006
Chronic myelogenous leukemia. Clinical journal of oncology nursing, 2005, Volume: 9, Issue:5 Topics: Age Distribution; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mutation; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Stem Cell Transplantation; Thiazoles; Translocation, Genetic	2005
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, Sep-15, Volume: 108, Issue:6 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Combined Modality Therapy; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Recombinant Proteins; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure	2006
Imatinib mesylate: A designer drug. The Journal of the Association of Physicians of India, 2006, Volume: 54 Topics: Benzamides; Eosinophilia; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines	2006
[Chronic myelogenous leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:7 Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Therapy, Combination; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2006
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. Hematological oncology, 2006, Volume: 24, Issue:4 Topics: Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Guidelines as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Mutation; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome	2006
[Molecular targeting therapy for chronic myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:1 Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2007
The challenges of targeting chronic myeloid leukemia stem cells. Clinical lymphoma & myeloma, 2007, Volume: 7 Suppl 2 Topics: ATP-Binding Cassette Transporters; Benzamides; Cell Differentiation; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Pyrimidines	2007
Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia. Clinical journal of oncology nursing, 2007, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nurse's Role; Nursing Assessment; Oncology Nursing; Philadelphia Chromosome; Piperazines; Practice Guidelines as Topic; Primary Health Care; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Thiazoles; Treatment Outcome	2007
Applying the discovery of the Philadelphia chromosome. The Journal of clinical investigation, 2007, Volume: 117, Issue:8 Topics: Benzamides; Biomarkers, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines	2007
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer, 2007, Sep-15, Volume: 110, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Survival Analysis; Thiazoles; Treatment Outcome	2007
What's blasting off in CML? ONS connect, 2007, Volume: 22, Issue:8 Suppl Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Monitoring; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Pyrimidines; Risk Factors; Thiazoles	2007
Imatinib mesylate in the treatment of hematologic malignancies. Expert opinion on biological therapy, 2007, Volume: 7, Issue:10 Topics: Animals; Antineoplastic Agents; Benzamides; Drug Interactions; Drug Resistance; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Treatment Outcome	2007
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. International journal of clinical oncology, 2007, Volume: 12, Issue:5 Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2007
Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology. American Society of Hematology. Education Program, 2007 Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation	2007
Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs, 2007, Volume: 67, Issue:17 Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Treatment Outcome	2007
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:18 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2007
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clinical therapeutics, 2007, Volume: 29, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Chemical; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcr; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Thiazoles	2007
[Research advance on molecular genetics of CML blast crisis]. Zhongguo shi yan xue ye xue za zhi, 2008, Volume: 16, Issue:1 Topics: Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic	2008
Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia & lymphoma, 2008, Volume: 49, Issue:7 Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines	2008
Chronic myelogenous leukemia. Current opinion in oncology, 2001, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines	2001
Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. British journal of haematology, 2001, Volume: 113, Issue:1 Topics: Animals; Apoptosis; Benzamides; Cell Adhesion; Cell Cycle; Cell Line, Transformed; Clinical Trials as Topic; Cytoskeleton; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Growth Substances; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Models, Animal; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Stem Cells; Telomere	2001
Mechanisms of transformation by the BCR/ABL oncogene. International journal of hematology, 2001, Volume: 73, Issue:3 Topics: Benzamides; Cell Transformation, Neoplastic; Cytoskeleton; Enzyme Activation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Oncogene Proteins, Fusion; Philadelphia Chromosome; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Protein Structure, Tertiary; Protein Transport; Pyrimidines; Reactive Oxygen Species; Signal Transduction	2001
[Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia]. Bulletin du cancer, 2001, Volume: 88, Issue:7 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Transplantation; Cancer Vaccines; Cell Adhesion; Drug Resistance, Neoplasm; Enzyme Inhibitors; Forecasting; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotides, Antisense; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction	2001
[Chronic myeloid leukemia and tyrosine kinase inhibitors]. La Revue de medecine interne, 2001, Volume: 22, Issue:9 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytogenetics; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors	2001
[Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60, Issue:1 Topics: Animals; Benzamides; Blast Crisis; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2002

Trials

41 trial(s) available for imatinib mesylate and Ph 1 Chromosome

Article	Year
Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood advances, 2022, 01-25, Volume: 6, Issue:2 Topics: Acute Disease; Adult; Dasatinib; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence	2022
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias. Leukemia research, 2021, Volume: 111 Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; Drug Tapering; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Philadelphia Chromosome; Prognosis; Pyrimidines; Quinolines; Retrospective Studies; Young Adult	2021
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. The Lancet. Haematology, 2023, Volume: 10, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dasatinib; Female; Humans; Imatinib Mesylate; Male; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome	2023
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study. Haematologica, 2023, Dec-01, Volume: 108, Issue:12 Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia; Nitriles; Philadelphia Chromosome; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors	2023
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA oncology, 2020, 03-01, Volume: 6, Issue:3 Topics: Antineoplastic Agents; Child; Child, Preschool; Dasatinib; Female; Humans; Imatinib Mesylate; Infant; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Treatment Outcome	2020
Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study. British journal of haematology, 2020, Volume: 190, Issue:1 Topics: Adult; Aged; Ambulatory Care; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Coronavirus Infections; COVID-19; Female; Humans; Imatinib Mesylate; Italy; Male; Middle Aged; Pandemics; Philadelphia Chromosome; Pneumonia, Viral; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2020
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 01-20, Volume: 36, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Female; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Phenotype; Philadelphia Chromosome; Protein Kinase Inhibitors; Quinolines; Time Factors; Treatment Outcome; Young Adult	2018
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:4 Topics: Adolescent; Adult; Aged; Allografts; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Survival Rate	2018
Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. Haematologica, 2019, Volume: 104, Issue:1 Topics: Adolescent; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Leukocyte Count; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate	2019
Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:8 Topics: Adolescent; Allografts; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Infant; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence; Survival Rate	2019
Feasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatric blood & cancer, 2013, Volume: 60, Issue:8 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Transplantation, Homologous	2013
[Efficacies of hematopoietic stem cell transplantation plus imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparative study]. Zhonghua yi xue za zhi, 2013, Feb-26, Volume: 93, Issue:8 Topics: Adolescent; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult	2013
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. Leukemia & lymphoma, 2015, Volume: 56, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Nuclear Proteins; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Verapamil; Vincristine; Young Adult	2015
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Health Status; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Quality of Life; Treatment Outcome	2014
Human organic cation transporter 1 protein levels of granulocytes can optimize imatinib therapy in patients with chronic myeloid leukemia. Acta haematologica, 2015, Volume: 133, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Female; Flow Cytometry; Gene Expression Regulation, Leukemic; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Organic Cation Transporter 1; Philadelphia Chromosome; Piperazines; Pyrimidines	2015
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood, 2015, Jun-11, Volume: 125, Issue:24 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Treatment Outcome; Young Adult	2015
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c- Haematologica, 2015, Volume: 100, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Administration Schedule; Febrile Neutropenia; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mucositis; Mutation; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrazoles	2015
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. American journal of hematology, 2015, Volume: 90, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Induction Chemotherapy; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Remission Induction; Survival Analysis; Transplantation, Homologous; Vincristine	2015
Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses. Leukemia & lymphoma, 2016, Volume: 57, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Body Surface Area; Body Weight; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome; Young Adult	2016
A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets. Cancer research and treatment, 2016, Volume: 48, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Tablets; Therapeutic Equivalency	2016
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Pyridazines; Treatment Outcome	2016
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:11 Topics: Adolescent; Adult; Aged; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Prognosis; Recurrence; Remission Induction; Secondary Prevention; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult	2016
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. The Lancet. Haematology, 2016, Volume: 3, Issue:12 Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Asia; Biomarkers, Pharmacological; Bone Marrow; Comparative Effectiveness Research; Cytogenetic Analysis; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Europe; Exanthema; Female; Fever; Follow-Up Studies; Headache; Hematologic Diseases; Humans; Imatinib Mesylate; Latin America; Leukemia, Myeloid, Chronic-Phase; Male; Metabolic Diseases; Middle Aged; Philadelphia Chromosome; Pyrimidines; Random Allocation; Treatment Failure	2016
Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood cancer journal, 2016, 12-09, Volume: 6, Issue:12 Topics: Adolescent; Adult; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Rituximab; Transplantation, Homologous; Treatment Outcome; Young Adult	2016
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL T Blood, 2009, May-07, Volume: 113, Issue:19 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunophenotyping; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult	2009
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica, 2010, Volume: 95, Issue:1 Topics: Adolescent; Adult; Benzamides; Child; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Pyrimidines; Remission Induction; Stem Cell Transplantation; Survival Rate; Treatment Outcome; Young Adult	2010
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-01, Volume: 27, Issue:31 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Young Adult	2009
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood, 2011, Jun-23, Volume: 117, Issue:25 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Survival Analysis; Young Adult	2011
Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative G British journal of haematology, 2011, Volume: 154, Issue:5 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Spain; Tissue Donors; Transplantation, Homologous; Treatment Outcome	2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet. Oncology, 2011, Volume: 12, Issue:9 Topics: Administration, Oral; Antineoplastic Agents; Australia; Benzamides; Brazil; Disease-Free Survival; Drug Administration Schedule; Europe; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Singapore; Survival Rate; Time Factors; Treatment Outcome; United States	2011
Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. Journal of hematology & oncology, 2012, Jun-08, Volume: 5 Topics: Adolescent; Adult; Benzamides; Child; Child, Preschool; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survival Rate; Transplantation, Homologous; Treatment Outcome; Young Adult	2012
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. The Lancet. Oncology, 2012, Volume: 13, Issue:9 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Incidence; Infant; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Assessment; Stem Cell Transplantation; Survival Rate	2012
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:1 Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Survival Rate; Time Factors; Transplantation, Autologous; Transplantation, Homologous; Unrelated Donors	2013
Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. Clinical and laboratory haematology, 2003, Volume: 25, Issue:2 Topics: Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Count; Cytogenetic Analysis; Drug Resistance; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Neutropenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Reticulin; Thrombocytopenia; Treatment Outcome	2003
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood, 2004, Nov-01, Volume: 104, Issue:9 Topics: Adolescent; Adult; Benzamides; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Infant; Leukemia; Pharmacokinetics; Philadelphia Chromosome; Piperazines; Pyrimidines; Salvage Therapy; Survival Analysis; Treatment Outcome	2004
Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood, 2007, Feb-15, Volume: 109, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Survival Analysis; Transplantation, Homologous	2007
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica, 2007, Volume: 92, Issue:6 Topics: Adult; Aged; Benzamides; Chromosome Aberrations; Clone Cells; Dasatinib; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Salvage Therapy; Thiazoles	2007
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica, 2008, Volume: 93, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Karyotyping; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Pyrimidines; Recurrence; Survival Rate; Transplantation, Homologous	2008
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. The New England journal of medicine, 2001, Apr-05, Volume: 344, Issue:14 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Pilot Projects; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Remission Induction	2001
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. The New England journal of medicine, 2002, Feb-28, Volume: 346, Issue:9 Topics: Administration, Oral; Analysis of Variance; Antineoplastic Agents; Benzamides; Blood Cell Count; Cytogenetics; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Regression Analysis	2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood, 2002, May-15, Volume: 99, Issue:10 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Cytarabine; Cytogenetic Analysis; Enzyme Inhibitors; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome	2002

Other Studies

276 other study(ies) available for imatinib mesylate and Ph 1 Chromosome

Article	Year
Management of chronic myeloid leukemia presenting with isolated thrombocytosis and complex Philadelphia chromosome: A case report. Medicine, 2021, Sep-03, Volume: 100, Issue:35 Topics: Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Thrombocytosis; Young Adult	2021
Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study. The Korean journal of internal medicine, 2021, Volume: 36, Issue:6 Topics: Asparaginase; Humans; Imatinib Mesylate; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies	2021
RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia. Cancer science, 2022, Volume: 113, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Core Binding Factor Alpha 2 Subunit; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Mutation; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2022
Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy. Journal of adolescent and young adult oncology, 2022, Volume: 11, Issue:6 Topics: Adult; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy	2022
[Intensive chemotherapy with tyrosine kinase inhibitors in philadelphia-positive acute lymphoblastic leukemia]. Revista medica de Chile, 2021, Volume: 149, Issue:9 Topics: Adolescent; Adult; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Young Adult	2021
Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia. Anales de pediatria, 2022, Volume: 96, Issue:4 Topics: Acute Disease; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2022
Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system. International journal of hematology, 2022, Volume: 116, Issue:4 Topics: Antineoplastic Agents; Cell Line; CRISPR-Associated Protein 9; CRISPR-Cas Systems; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nucleotides; Oligodeoxyribonucleotides; Philadelphia Chromosome; Poly (ADP-Ribose) Polymerase-1; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; RNA, Guide, Kinetoplastida	2022
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood advances, 2022, 09-27, Volume: 6, Issue:18 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Imatinib Mesylate; Imidazoles; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Recurrence; Young Adult	2022
Cytogenetical and hematological analysis of chronic myelogenous leukemia patients with a novel case 52XX, t (1;9;22) (q23.3; q34; q11.2), +6, +8, i(9) (q10;q10), +18,+19,+21+der22 t(9;22)(q34;q11). Medicine, 2022, Nov-11, Volume: 101, Issue:45 Topics: Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Translocation, Genetic	2022
Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia? Hematology. American Society of Hematology. Education Program, 2022, 12-09, Volume: 2022, Issue:1 Topics: Adult; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors	2022
Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China. BMC health services research, 2022, Dec-26, Volume: 22, Issue:1 Topics: Child; China; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years	2022
Acute kidney injury and delayed methotrexate clearance in an adult patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia treated with imatinib. European journal of hospital pharmacy : science and practice, 2023, Volume: 30, Issue:5 Topics: Acute Kidney Injury; Adult; Female; Humans; Imatinib Mesylate; Methotrexate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2023
Establishment and Characterization of an Acute Lymphocytic Leukemia Cell Line Expressing CD13 and CD33 with a Complex Philadelphia Translocation. Internal medicine (Tokyo, Japan), 2023, Volume: 62, Issue:5 Topics: Adult; Cell Line; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sialic Acid Binding Ig-like Lectin 3	2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica, 2023, 09-01, Volume: 108, Issue:9 Topics: Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Philadelphia Chromosome; Protein Kinase Inhibitors	2023
Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response. Annals of hematology, 2023, Volume: 102, Issue:7 Topics: Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Prospective Studies; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome	2023
Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison. Advances in therapy, 2023, Volume: 40, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2023
Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China. BMC health services research, 2023, Jun-19, Volume: 23, Issue:1 Topics: Child; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines	2023
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer, 2023, 12-01, Volume: 129, Issue:23 Topics: Aged; Humans; Imatinib Mesylate; Income; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; United States	2023
Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer science, 2019, Volume: 110, Issue:10 Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dasatinib; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult	2019
Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Leukemia & lymphoma, 2020, Volume: 61, Issue:2 Topics: Adolescent; Humans; Imatinib Mesylate; Male; Oncogene Proteins, Fusion; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor beta; Trans-Activators; Transcription Factors; Treatment Outcome	2020
Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis. Oncology reports, 2019, Volume: 42, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Clonal Evolution; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Treatment Outcome; Young Adult	2019
Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells. Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:2 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Philadelphia Chromosome; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridazines; Pyrimidines	2020
Optimizing Targeted Therapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA oncology, 2020, 03-01, Volume: 6, Issue:3 Topics: Acute Disease; Child; Dasatinib; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2020
Dasatinib versus imatinib in paediatric ALL. Nature reviews. Clinical oncology, 2020, Volume: 17, Issue:4 Topics: Child; Dasatinib; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2020
An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. British journal of haematology, 2020, Volume: 189, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Dasatinib; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Retrospective Studies	2020
Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia. Journal of pediatric hematology/oncology, 2021, 03-01, Volume: 43, Issue:2 Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, B-Cell; Male; Methotrexate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Young Adult	2021
JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). International journal of hematology, 2020, Volume: 112, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Consolidation Chemotherapy; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Philadelphia Chromosome; Practice Guidelines as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome; World Health Organization; Young Adult	2020
CD9 knockdown suppresses cell proliferation, adhesion, migration and invasion, while promoting apoptosis and the efficacy of chemotherapeutic drugs and imatinib in Ph+ ALL SUP‑B15 cells. Molecular medicine reports, 2020, Volume: 22, Issue:4 Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Lentivirus; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; RNA, Small Interfering; Signal Transduction; Tetraspanin 29	2020
[Chronic myeloid leukemia: update on treatment and survival prediction]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:9 Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival	2020
[Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:9 Topics: Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2020
A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study. Leukemia, 2021, Volume: 35, Issue:7 Topics: Adolescent; Adult; Aged; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Transplantation, Homologous; Young Adult	2021
Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation. Asia-Pacific journal of clinical oncology, 2022, Volume: 18, Issue:1 Topics: Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Translocation, Genetic	2022
Improvement of Bone Marrow Necrosis by Tyrosine Kinase Inhibitor Substitution in a Pediatric Patient With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Journal of pediatric hematology/oncology, 2022, Mar-01, Volume: 44, Issue:2 Topics: Bone Marrow; Child; Humans; Imatinib Mesylate; Male; Necrosis; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2022
Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias. BMC cancer, 2021, Apr-29, Volume: 21, Issue:1 Topics: Absorptiometry, Photon; Adolescent; Age Determination by Skeleton; Cancer Survivors; Child; Dasatinib; Echocardiography; Electrocardiography; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Molecular Targeted Therapy; Philadelphia Chromosome; Population Surveillance; Protein Kinase Inhibitors; Retrospective Studies; Thyrotropin	2021
Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Frontiers of medicine, 2017, Volume: 11, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Multivariate Analysis; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult	2017
Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. Leukemia research, 2017, Volume: 59 Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; RNA, Messenger; Survival Rate	2017
Philadelphia Chromosome Positive de novo Acute Myeloid Leukemia. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2016, Volume: 26, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Rare Diseases; Recurrence; Remission Induction; Treatment Outcome; Young Adult	2016
The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML. Blood, 2017, 09-07, Volume: 130, Issue:10 Topics: Adult; Antineoplastic Agents; Blast Crisis; Bone Marrow; Chromosomes, Human, Pair 8; Genes, myc; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Isochromosomes; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Protein Kinase Inhibitors	2017
Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia & lymphoma, 2018, Volume: 59, Issue:10 Topics: Adult; Afibrinogenemia; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrinogen; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult	2018
[The molecular-cytogenetic characterization and tyrosine kinase inhibitors efficacy in newly diagnosed chronic phase CML patients with variant Philadelphia chromosomes]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2018, Mar-14, Volume: 39, Issue:3 Topics: Cytogenetics; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Philadelphia Chromosome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases	2018
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. Annals of hematology, 2018, Volume: 97, Issue:9 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Remission Induction; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult	2018
[Clinical Characteristics and Prognosis of patients with Variant Philadelphia Chromosome Positive Leukemia]. Zhongguo shi yan xue ye xue za zhi, 2018, Volume: 26, Issue:4 Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Philadelphia Chromosome; Prognosis	2018
Recurrent chronic myeloid leukemia with t (9;22;16) (q34; q11; p13) treated by nilotinib: A case report. Medicine, 2018, Volume: 97, Issue:42 Topics: Antineoplastic Agents; Chromosomes, Human, 16-18; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Neoplasm Recurrence, Local; Philadelphia Chromosome; Pyrimidines; Translocation, Genetic	2018
Imatinib stimulates prostaglandin E The Journal of allergy and clinical immunology, 2019, Volume: 143, Issue:2 Topics: Abelson murine leukemia virus; Cytokines; Dinoprostone; Humans; Imatinib Mesylate; Inflammation; Leukemia; Lipopolysaccharides; Monocytes; NF-kappa B; Philadelphia Chromosome; Platelet Activation; Proto-Oncogene Proteins c-bcr; Receptors, Prostaglandin E, EP4 Subtype; Signal Transduction; Th1-Th2 Balance; Thromboxane A2; U937 Cells	2019
A chronic myeloid leukemia case with a variant translocation t(11;22) (q23;q11.2): masked Philadelphia or simple variant translocation? The Pan African medical journal, 2018, Volume: 30 Topics: Adult; Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Translocation, Genetic	2018
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. The Lancet. Haematology, 2018, Volume: 5, Issue:12 Topics: Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Infant; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Survival Analysis; Treatment Outcome	2018
B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 Anticancer research, 2019, Volume: 39, Issue:1 Topics: DNA Mutational Analysis; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Recurrence; Remission Induction; Transplantation, Autologous	2019
Demographics and Outcome of Philadelphia-positive ALL in a Pediatric Population in North India: a Single-center Experience. Journal of pediatric hematology/oncology, 2019, Volume: 41, Issue:5 Topics: Bone Marrow Examination; Central Nervous System Neoplasms; Child; Female; Humans; Imatinib Mesylate; India; Kaplan-Meier Estimate; Leukocyte Count; Male; Neutropenia; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Survival Analysis; Treatment Outcome	2019
[Pre-therapeutic and evolutive characteristics of patients suffering from chronic myeloid leukemia, in Abidjan, Ivory Coast]. Bulletin du cancer, 2019, Volume: 106, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Blood Cell Count; Chromosome Aberrations; Cote d'Ivoire; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Cells, Circulating; Philadelphia Chromosome; Prognosis; Remission Induction; Retrospective Studies; Socioeconomic Factors; Young Adult	2019
Huaier extract enhances the treatment efficacy of imatinib in Ik6 Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 117 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Complex Mixtures; Disease Models, Animal; Fusion Proteins, bcr-abl; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Male; Mice, Inbred BALB C; Philadelphia Chromosome; Plant Extracts; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Trametes; Treatment Outcome	2019
Cutaneous manifestations in chronic myeloid leukemia in chronic phase treated with imatinib. International journal of dermatology, 2019, Volume: 58, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Eruptions; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pakistan; Philadelphia Chromosome; Protein Kinase Inhibitors; Time Factors; Young Adult	2019
[The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:1 Topics: Adolescent; Adult; Aged; Asian People; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Young Adult	2013
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood, 2013, Aug-15, Volume: 122, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult	2013
Post-fracture excessive callus formation in a child on imatinib therapy. Pediatric blood & cancer, 2013, Volume: 60, Issue:12 Topics: Antineoplastic Agents; Benzamides; Bony Callus; Child, Preschool; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tibial Fractures	2013
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood, 2014, Feb-06, Volume: 123, Issue:6 Topics: Adolescent; Adult; Aged; Benzamides; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Remission Induction; Survival Rate; Transplantation, Homologous; Young Adult	2014
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood, 2014, Mar-13, Volume: 123, Issue:11 Topics: Antineoplastic Agents; Benzamides; Child; Chromosome Aberrations; Cohort Studies; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Sequence Deletion; Survival Rate	2014
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer, 2014, May-15, Volume: 120, Issue:10 Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Drug Administration Schedule; Female; Flow Cytometry; Genes, T-Cell Receptor; Humans; Imatinib Mesylate; Induction Chemotherapy; Infant; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome	2014
Ph+ ALL: imatinib grows older with patients. Blood, 2014, Feb-06, Volume: 123, Issue:6 Topics: Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2014
[Prognostic significance of Ph-positive acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Young Adult	2014
[Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
[Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
A dimorphic blast population demonstrates Philadelphia-positive mixed phenotype acute leukaemia. Pathology, 2014, Volume: 46, Issue:3 Topics: Adult; Benzamides; Biopsy, Needle; Bone Marrow; Diagnosis, Differential; Female; Flow Cytometry; Granulocyte Precursor Cells; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Induction Chemotherapy; Karyotyping; Leukemia, Biphenotypic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenotype; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines	2014
[Outcome of autologous hematopoietic stem cell transplantation in combination with imatinib for 16 cases of Philadelphia chromosome positive acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2014, Volume: 35, Issue:3 Topics: Adolescent; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Autologous; Young Adult	2014
Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. Oncotarget, 2014, Mar-15, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Heme Oxygenase-1; Humans; Imatinib Mesylate; Maleates; Metalloporphyrins; Nitrogen Mustard Compounds; Philadelphia Chromosome; Piperazines; Polyethylene Glycols; Polystyrenes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Messenger	2014
Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. European journal of haematology, 2014, Volume: 93, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Surface; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Phenotype; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult	2014
Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:7 Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Benzamides; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Imatinib Mesylate; Immunosuppressive Agents; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
Rapid sequential gain of ABL1 kinase domain mutations with a complex karyotype in the progression of chronic myelogenous leukemia. Annals of laboratory medicine, 2014, Volume: 34, Issue:5 Topics: Base Sequence; Benzamides; Bone Marrow; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sequence Analysis, DNA; Thiazoles; Translocation, Genetic	2014
Stromal cells attenuate the cytotoxicity of imatinib on Philadelphia chromosome-positive leukemia cells by up-regulating the VE-cadherin/β-catenin signal. Leukemia research, 2014, Volume: 38, Issue:12 Topics: Antigens, CD; Antineoplastic Agents; Benzamides; beta Catenin; Cadherins; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia; Neoplasm Proteins; Philadelphia Chromosome; Piperazines; Pyrimidines; Signal Transduction; Stromal Cells; Up-Regulation	2014
[Clinical study of 32 patients with adult Philadelphia chromosome-positive acute lymphoblastic leukemia]. Zhongguo shi yan xue ye xue za zhi, 2014, Volume: 22, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retrospective Studies; Treatment Outcome	2014
Ph-negative isolated myeloid sarcoma with NPM1 gene mutation in adolescent with Ph-positive chronic myeloid leukemia in remission after treatment with allogeneic bone marrow transplantation and imatinib mesylate. Pediatric blood & cancer, 2015, Volume: 62, Issue:6 Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Child; Combined Modality Therapy; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Nuclear Proteins; Nucleophosmin; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Sarcoma, Myeloid; Transplantation, Homologous	2015
Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood, 2015, Apr-02, Volume: 125, Issue:14 Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Carrier Proteins; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Chaperones; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; RNA, Messenger; Tumor Cells, Cultured	2015
Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6 Topics: Acute Disease; Adult; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression; Graft vs Host Disease; Haplotypes; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Recurrence; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors	2015
Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:6 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Child; Female; Hepatitis; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Pyrimidines	2015
[Effects of stromal cells on sentitivity to imatinib in Sup-B15 Philadelphia chromosome positive acute lymphoblastic leukemia cells]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:6 Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Stromal Cells	2015
Pediatric Acute Lymphoblastic Leukemia: From Diagnosis to Prognosis. Pediatric annals, 2015, Volume: 44, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Child, Preschool; Humans; Imatinib Mesylate; Injections, Spinal; Male; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis	2015
The antileukemia effect of metformin in the Philadelphia chromosome-positive leukemia cell line and patient primary leukemia cell. Anti-cancer drugs, 2015, Volume: 26, Issue:9 Topics: Antineoplastic Agents; Autophagy; Benzamides; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; MAP Kinase Signaling System; Metformin; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured	2015
[Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children]. Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2015, Volume: 17, Issue:8 Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2015
Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia. PloS one, 2015, Volume: 10, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Eukaryotic Initiation Factor-4E; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Ribavirin; Signal Transduction; TOR Serine-Threonine Kinases	2015
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias. Oncotarget, 2015, Oct-20, Volume: 6, Issue:32 Topics: Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Proto-Oncogene Proteins c-pim-1; Pyridazines; Tumor Cells, Cultured	2015
Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia. International journal of hematology, 2015, Volume: 102, Issue:6 Topics: Adolescent; Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dasatinib; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Young Adult	2015
Comprehensive Molecular Analyses in a Case of Masked Philadelphia Chronic Myeloid Leukemia. Cytogenetic and genome research, 2015, Volume: 147, Issue:1 Topics: Aged, 80 and over; Antineoplastic Agents; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microarray Analysis; Philadelphia Chromosome; Polymerase Chain Reaction	2015
The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2016, Mar-05, Volume: 33, Issue:1 Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Treatment Outcome	2016
Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting. European journal of clinical pharmacology, 2016, Volume: 72, Issue:12 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors	2016
Response: Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting. European journal of clinical pharmacology, 2016, Volume: 72, Issue:12 Topics: Antineoplastic Agents; Benzamides; Cyclosporine; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2016
Predictive and Prognostic Implications of Variant Philadelphia Translocations in CML: Experience From a Tertiary Oncology Center in Southern India. Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Translocation, Genetic; Young Adult	2017
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data. Journal of medical economics, 2017, Volume: 20, Issue:4 Topics: Aged; Antineoplastic Agents; Cost-Benefit Analysis; Dasatinib; Disease-Free Survival; Fees, Pharmaceutical; Female; Health Expenditures; Health Services; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Econometric; Philadelphia Chromosome; Pyrimidines; Quality-Adjusted Life Years; Time Factors	2017
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American journal of hematology, 2017, Volume: 92, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Disease-Free Survival; Female; Gene Deletion; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyridazines; Survival Rate; Translocation, Genetic; Treatment Outcome; Young Adult	2017
Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Pediatric blood & cancer, 2017, Volume: 64, Issue:8 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Salvage Therapy	2017
Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence. Leukemia, 2017, Volume: 31, Issue:4 Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Remission Induction	2017
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood, 2008, Nov-01, Volume: 112, Issue:9 Topics: Adolescent; Adult; Aged; Alternative Splicing; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Dasatinib; DNA Primers; DNA, Neoplasm; Drug Resistance, Neoplasm; Genes, abl; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Middle Aged; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles	2008
Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions. International journal of hematology, 2008, Volume: 88, Issue:3 Topics: Adult; Benzamides; Cyclosporine; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Living Donors; Lymphocyte Transfusion; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Siblings; Transplantation, Homologous	2008
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. Haematologica, 2008, Volume: 93, Issue:11 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Colony-Forming Units Assay; Drug Resistance; Fatty Acids, Unsaturated; Fusion Proteins, bcr-abl; Gene Amplification; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic	2008
Chronic myeloid leukemia in two patients with gastrointestinal stromal tumor. International journal of hematology, 2008, Volume: 88, Issue:3 Topics: Aged; Benzamides; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines	2008
Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. Bone marrow transplantation, 2009, Volume: 43, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Regression Analysis; Retrospective Studies; Young Adult	2009
Haemorrhagic complications associated with reduced alpha2-plasmin inhibitor during imatinib use in a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia. Leukemia research, 2009, Volume: 33, Issue:6 Topics: Aged; Antifibrinolytic Agents; Antineoplastic Agents; Benzamides; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2009
Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia. International journal of laboratory hematology, 2008, Volume: 30, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 8; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Trisomy	2008
Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia, 2009, Volume: 23, Issue:5 Topics: Adult; Aged; Antigens, CD34; Benzamides; Biomarkers, Tumor; Female; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2009
Fluorescence in situ hybridization dissection of a chronic myeloid leukemia case bearing the apparently balanced translocations (9;22)(q34;q11.2) and (11;11)(p15;q13). Cancer genetics and cytogenetics, 2009, Jan-01, Volume: 188, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Deletion; Chromosome Mapping; Chromosome Painting; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic; Tumor Cells, Cultured	2009
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-20, Volume: 27, Issue:3 Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles	2009
Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia. Leukemia research, 2009, Volume: 33, Issue:7 Topics: Adult; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-abl; Pyrimidines	2009
Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. European journal of haematology, 2009, Volume: 83, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; DNA Primers; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Genes, abl; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Valproic Acid	2009
Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia. Methods in molecular biology (Clifton, N.J.), 2009, Volume: 487 Topics: Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA, Small Interfering	2009
High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene. International journal of hematology, 2009, Volume: 90, Issue:1 Topics: Benzamides; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia; Male; Mutation; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; U937 Cells	2009
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22 Topics: Benzamides; Cause of Death; Cohort Studies; Cytogenetics; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Probability; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome	2009
Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer. Thrombosis and haemostasis, 2009, Volume: 101, Issue:6 Topics: Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Agents; Benzamides; Blood Coagulation Tests; Cross-Sectional Studies; Female; Follow-Up Studies; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thrombocytopenia; Treatment Outcome; Withholding Treatment	2009
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Leukemia research, 2009, Volume: 33, Issue:12 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines	2009
A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement. International journal of hematology, 2009, Volume: 90, Issue:2 Topics: Adult; Antineoplastic Agents; Asian People; Benzamides; Chromosome Aberrations; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic	2009
[Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases]. Terapevticheskii arkhiv, 2009, Volume: 81, Issue:7 Topics: Adult; Benzamides; Bone Marrow Cells; Chromosomes, Human, Pair 8; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Trisomy	2009
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Hematological oncology, 2010, Volume: 28, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Republic of Korea; Salvage Therapy; Thiazoles; Treatment Outcome; Young Adult	2010
Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment. Leukemia research, 2010, Volume: 34, Issue:2 Topics: Adult; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction	2010
Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy. Leukemia, 2010, Volume: 24, Issue:1 Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antigens, CD34; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2010
Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia. Genetic testing and molecular biomarkers, 2009, Volume: 13, Issue:5 Topics: Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Pyrimidines	2009
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood, 2010, Jan-14, Volume: 115, Issue:2 Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Philadelphia Chromosome; Piperazines; Pyrimidines	2010
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematology. American Society of Hematology. Education Program, 2009 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System; Child; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemic Infiltration; Mutation; Neoplasm Proteins; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Secondary Prevention; Thiazoles; Transplantation Conditioning	2009
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica, 2010, Volume: 95, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome	2010
Possible alternative strategy for stage I imatinib-sensitive testicular seminoma; lessons from a case associated with Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5 Topics: Benzamides; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Seminoma; Testicular Neoplasms	2010
Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia. Journal of hematology & oncology, 2010, Apr-09, Volume: 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Clone Cells; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes; Treatment Outcome	2010
Reversible cardiotoxicity with tyrosine kinase inhibitors. Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:2 Topics: Adult; Benzamides; Cardiotoxins; Central Nervous System Neoplasms; Dasatinib; Fatal Outcome; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Ventricular Dysfunction, Left	2010
Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression. Leukemia research, 2010, Volume: 34, Issue:9 Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Megakaryoblastic, Acute; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Thiazoles	2010
Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation. Cancer genetics and cytogenetics, 2010, Volume: 199, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Bone Marrow; Cell Transformation, Neoplastic; Clone Cells; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Sequence Data; Philadelphia Chromosome; Piperazines; Polyploidy; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Time Factors	2010
Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. Leukemia, 2010, Volume: 24, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult	2010
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer genetics and cytogenetics, 2010, Volume: 199, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome	2010
Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-20, Volume: 28, Issue:18 Topics: Benzamides; Health Planning Guidelines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome	2010
[Clinical study of imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2010, Volume: 31, Issue:3 Topics: Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2010
[Case of pediatric chronic myeloid leukemia with bilateral visual loss onset]. Nippon Ganka Gakkai zasshi, 2010, Volume: 114, Issue:5 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Child; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome; Vision, Low	2010
Membranoproliferative glomerulonephritis secondary to chronic myeloid leukemia. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2010, Volume: 21, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Diuretics; Glomerulonephritis, Membranoproliferative; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Treatment Outcome	2010
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer cell, 2010, Jul-13, Volume: 18, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Calcium; Cell Proliferation; Cyclosporine; Cytokines; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Wnt Proteins	2010
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 2010, Nov-04, Volume: 116, Issue:18 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles	2010
Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid : official journal of the American Thyroid Association, 2010, Volume: 20, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland	2010
Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience. Vojnosanitetski pregled, 2010, Volume: 67, Issue:10 Topics: Aged; Benzamides; Blood Cell Count; Bone Marrow; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult	2010
Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism. Cytogenetic and genome research, 2011, Volume: 132, Issue:4 Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Inversion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-gamma; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metaphase; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic	2011
Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene. International journal of hematology, 2011, Volume: 93, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic; Treatment Outcome	2011
[The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:5 Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Daunorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Pyrimidines	2010
[Acute leukemia of ambiguous lineage with monosomy 7 and Philadelphia chromosome]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:1 Topics: Acute Disease; Aged; Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Diagnosis, Differential; Fatal Outcome; Female; Heart Failure; Humans; Imatinib Mesylate; Leukemia; Philadelphia Chromosome; Piperazines; Pyrimidines	2011
[Loss of Philadelphia chromosome after graft failure following cord blood transplantation for Philadelphia chromosome-positive acute myeloid leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:2 Topics: Benzamides; Fetal Blood; Graft Rejection; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Treatment Outcome	2011
[Atypical myeloproliferative neoplasm with a small population of Philadelphia chromosome-positive clones in the bone marrow]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:2 Topics: Benzamides; Bone Marrow; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Myeloproliferative Disorders; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocytosis; Translocation, Genetic	2011
Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; DNA Probes; Female; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Retrospective Studies; Translocation, Genetic	2012
Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib. Leukemia & lymphoma, 2011, Volume: 52, Issue:7 Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Duplication; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles	2011
Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis. Leukemia research, 2011, Volume: 35, Issue:7 Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Benzamides; Blotting, Western; Endoplasmic Reticulum; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thapsigargin; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tunicamycin	2011
Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. Cancer genetics, 2011, Volume: 204, Issue:4 Topics: Antineoplastic Agents; Benzamides; Cloning, Molecular; Cytogenetics; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic	2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood, 2011, Sep-29, Volume: 118, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrimidines; Young Adult	2011
Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia. Leukemia & lymphoma, 2012, Volume: 53, Issue:3 Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Chromosomes, Human, Pair 8; Clone Cells; Dasatinib; DNA Mutational Analysis; Genomic Instability; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Philadelphia Chromosome; Piperazines; Preleukemia; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Selection, Genetic; Thiazoles; Trisomy	2012
First-line therapy for CML: nilotinib comes of age. The Lancet. Oncology, 2011, Volume: 12, Issue:9 Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2011
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy. Pediatric blood & cancer, 2012, Volume: 59, Issue:3 Topics: Azacitidine; Benzamides; Child, Preschool; Chromosome Aberrations; Decitabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation	2012
Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib. Leukemia, 2012, Volume: 26, Issue:4 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Philadelphia Chromosome; Piperazines; Pyrimidines	2012
Allogeneic hematopoietic stem cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in children and adolescents: a retrospective multicenter study of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:6 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Disease-Free Survival; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Italy; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Retrospective Studies; Secondary Prevention; Transplantation, Homologous; Young Adult	2012
Chronic myelogenous leukemia. Preface. Hematology/oncology clinics of North America, 2011, Volume: 25, Issue:5 Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2011
Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. International journal of hematology, 2011, Volume: 94, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Homologous; Treatment Outcome	2011
[Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib]. Vojnosanitetski pregled, 2011, Volume: 68, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult	2011
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia, 2012, Volume: 26, Issue:7 Topics: Adolescent; Adult; Aged; Benzamides; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prevalence; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Young Adult	2012
Prolonged survival with imatinib mesylate combined with chemotherapy and allogeneic stem cell transplantation in de novo Ph+ acute myeloid leukemia. Acta haematologica, 2012, Volume: 127, Issue:3 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Daunorubicin; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Homologous; Young Adult	2012
Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report. Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:11 Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous; Young Adult	2011
Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate. Cancer genetics, 2011, Volume: 204, Issue:12 Topics: Adult; Antineoplastic Agents; Benzamides; Clonal Evolution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Translocation, Genetic	2011
Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. British journal of haematology, 2012, Volume: 157, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents; Base Sequence; Benzamides; Child; Child, Preschool; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Infant; Male; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Young Adult	2012
Philadelphia chromosome-negative myeloproliferative neoplasm with a novel platelet-derived growth factor receptor-β rearrangement responsive to imatinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-20, Volume: 30, Issue:9 Topics: Antineoplastic Agents; Benzamides; Gene Rearrangement; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome	2012
[Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2011, Volume: 32, Issue:12 Topics: Adult; Benzamides; Female; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Retrospective Studies	2011
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. International journal of hematology, 2012, Volume: 95, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Female; Fusion Proteins, bcr-abl; Germany; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome; United Kingdom; United States	2012
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia. Gene, 2012, Jun-15, Volume: 501, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine	2012
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood, 2012, Jul-26, Volume: 120, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult	2012
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. Blood, 2012, Jul-26, Volume: 120, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult	2012
Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia, 2012, Volume: 26, Issue:11 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Young Adult	2012
Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia. The Lancet. Oncology, 2012, Volume: 13, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2012
A case of childhood T cell acute lymphoblastic leukemia with a complex t(9;9) and homozygous deletion of CDKN2A gene associated with a Philadelphia-positive minor subclone. Blood cells, molecules & diseases, 2013, Volume: 50, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Chromosomes, Human, Pair 9; Clonal Evolution; Clone Cells; Fusion Proteins, bcr-abl; Gene Deletion; Genes, p16; Humans; Imatinib Mesylate; Karyotype; Male; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Translocation, Genetic	2013
p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16). International journal of hematology, 2012, Volume: 96, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 16; Combined Modality Therapy; Cytarabine; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelomonocytic, Acute; Male; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction	2012
Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome. Annals of hematology, 2013, Volume: 92, Issue:2 Topics: Abnormal Karyotype; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Brazil; Chromosomes, Human; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Translocation, Genetic; Treatment Outcome; Young Adult	2013
Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias. Leukemia research, 2013, Volume: 37, Issue:1 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Interleukin-6; Leukemia; Philadelphia Chromosome; Piperazines; Pyrimidines	2013
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia. Acta haematologica, 2013, Volume: 129, Issue:2 Topics: Aged; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metaphase; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2013
PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells. International journal of oncology, 2013, Volume: 42, Issue:2 Topics: Apoptosis; Benzamides; Cell Adhesion; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Pyrimidines; Signal Transduction	2013
The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology (Amsterdam, Netherlands), 2013, Volume: 18, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome	2013
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Cancer, 2002, Jun-01, Volume: 94, Issue:11 Topics: Antineoplastic Agents; Benzamides; Blood Cell Count; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Middle Aged; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Prognosis; Pyrimidines; Remission Induction; T-Lymphocytes; Treatment Outcome	2002
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer, 2002, May-15, Volume: 94, Issue:10 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Harringtonines; Homoharringtonine; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay	2002
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood, 2002, Sep-01, Volume: 100, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis	2002
Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. British journal of haematology, 2002, Volume: 118, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome	2002
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood, 2003, Mar-01, Volume: 101, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Blood Cells; Bone Marrow Cells; Clone Cells; Cohort Studies; Cytarabine; Dosage Compensation, Genetic; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Idarubicin; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, Androgen; Remission Induction	2003
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia, 2002, Volume: 16, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Caspase 3; Caspases; Cell Division; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Philadelphia Chromosome; Piperazines; Pyrimidines; Tumor Cells, Cultured	2002
Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia. Leukemia & lymphoma, 2002, Volume: 43, Issue:11 Topics: Benzamides; Clone Cells; Disease Progression; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines	2002
Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome. Leukemia, 2003, Volume: 17, Issue:2 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Imatinib Mesylate; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; RNA, Messenger; Transcription, Genetic	2003
Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib. Leukemia, 2003, Volume: 17, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Time Factors	2003
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica, 2003, Volume: 88, Issue:2 Topics: Benzamides; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Thrombocytopenia	2003
Chromosomal abnormalities in Philadelphia (Ph)-negative cells of patients with chronic myeloide leukemia treated with Imatinib (ST1571). Haematologica, 2003, Volume: 88, Issue:2 Topics: Adult; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines	2003
Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood, 2003, Mar-15, Volume: 101, Issue:6 Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Skin Diseases	2003
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia, 2003, Volume: 17, Issue:3 Topics: Adult; Aged; Benzamides; Case-Control Studies; Chromosomes, Human, Pair 8; Clone Cells; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Trisomy	2003
Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones. Leukemia, 2003, Volume: 17, Issue:3 Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines	2003
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. European journal of haematology, 2003, Volume: 70, Issue:4 Topics: Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosome Aberrations; Chromosome Painting; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fatal Outcome; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous	2003
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia, 2003, Volume: 17, Issue:5 Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Blood Component Removal; Cohort Studies; Enzyme Inhibitors; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome	2003
The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines	2003
[Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction	2003
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Experimental hematology, 2003, Volume: 31, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 8; Clone Cells; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pancytopenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Trisomy	2003
[Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia]. Ai zheng = Aizheng = Chinese journal of cancer, 2003, Volume: 22, Issue:8 Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Follow-Up Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines	2003
A 41-year-old woman with chronic myelogenous leukemia. JAMA, 2003, Aug-27, Volume: 290, Issue:8 Topics: Adult; Antineoplastic Agents; Benzamides; Decision Making; Fatigue; Female; Headache; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Stem Cell Transplantation	2003
Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia. International journal of hematology, 2003, Volume: 78, Issue:2 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; RNA, Messenger	2003
Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case. Leukemia, 2003, Volume: 17, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines	2003
Chromosomal abnormalities in Ph- cells of patients on imatinib. Blood, 2003, Oct-01, Volume: 102, Issue:7 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2003
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer, 2003, Oct-01, Volume: 98, Issue:7 Topics: Aged; Analysis of Variance; Antineoplastic Agents; Benzamides; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Multivariate Analysis; Philadelphia Chromosome; Piperazines; Probability; Prognosis; Pyrimidines; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome	2003
Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis. Oncogene, 2003, Oct-09, Volume: 22, Issue:44 Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Benzamides; Enzyme Inhibitors; Fibroblasts; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Monocytes; Oxides; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Isoforms; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transgenes; Translocation, Genetic; Tumor Cells, Cultured; U937 Cells; Up-Regulation	2003
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. British journal of haematology, 2003, Volume: 123, Issue:3 Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Stem Cell Transplantation; Stem Cells	2003
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer, 2003, Dec-15, Volume: 98, Issue:12 Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Survival Rate; Treatment Outcome	2003
[Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2003, Volume: 23, Issue:12 Topics: Adult; Antigens, CD34; Benzamides; Follow-Up Studies; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous	2003
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer research, 2004, Jan-15, Volume: 64, Issue:2 Topics: Antineoplastic Agents; Benzamides; Blotting, Northern; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Terminal Repeat Sequences	2004
Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica, 2004, Volume: 89, Issue:1 Topics: Adult; Aged; Benzamides; Bone Marrow; Cytogenetic Analysis; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction	2004
Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib. Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:2 Topics: Benzamides; Blast Crisis; Bone Marrow; Genes, abl; Humans; Hyperplasia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic	2004
Novel chromosomal aberrations in Philadelphia negative cells of chronic myelogenous leukemia patients on imatinib: report of three cases. Leukemia, 2004, Volume: 18, Issue:5 Topics: Adult; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines	2004
Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital. JPMA. The Journal of the Pakistan Medical Association, 2004, Volume: 54, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetics; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Treatment Outcome	2004
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood, 2004, Apr-15, Volume: 103, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drugs, Investigational; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Therapies, Investigational	2004
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood, 2004, Sep-01, Volume: 104, Issue:5 Topics: Antigens, CD19; Antigens, CD34; Antineoplastic Agents; Benzamides; Burkitt Lymphoma; Cell Death; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Liposomes; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured	2004
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood, 2004, Oct-01, Volume: 104, Issue:7 Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Philadelphia Chromosome; Piperazines; Proportional Hazards Models; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome	2004
Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. International journal of hematology, 2004, Volume: 80, Issue:1 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Benzamides; Clone Cells; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Rituximab; RNA, Messenger	2004
Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation. Leukemia & lymphoma, 2004, Volume: 45, Issue:7 Topics: Adult; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Transplantation Chimera; Transplantation, Homologous; Trisomy	2004
[Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome]. Terapevticheskii arkhiv, 2004, Volume: 76, Issue:7 Topics: Adult; Benzamides; Eosinophils; Fusion Proteins, bcr-abl; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Pyrimidines; Treatment Outcome	2004
CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell? Laboratory hematology : official publication of the International Society for Laboratory Hematology, 2004, Volume: 10, Issue:3 Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2004
Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML). American journal of hematology, 2004, Volume: 77, Issue:4 Topics: Benzamides; Chromosomes, Human, Pair 8; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Trisomy	2004
Every case of essential thrombocythemia should be tested for the Philadelphia chromosome. American journal of hematology, 2005, Volume: 78, Issue:1 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Chronic Disease; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocythemia, Essential	2005
Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib. Leukemia, 2005, Volume: 19, Issue:3 Topics: Adult; Aged; Antigens, CD34; Benzamides; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Phylogeny; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction	2005
In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Leukemia & lymphoma, 2005, Volume: 46, Issue:2 Topics: Benzamides; Cell Survival; Child; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Male; Mutation, Missense; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2005
Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia, 2005, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clone Cells; Female; Hematopoiesis; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines	2005
Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib. The Lancet. Oncology, 2005, Volume: 6, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Blindness; Central Nervous System; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 6; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Retina; Trisomy	2005
The Philadelphia translocation and pre-existing myeloproliferative disorders. British journal of haematology, 2005, Volume: 128, Issue:5 Topics: Antineoplastic Agents; Benzamides; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic	2005
Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib. American journal of ophthalmology, 2005, Volume: 139, Issue:4 Topics: Anterior Chamber; Antineoplastic Agents; Aqueous Humor; Benzamides; Eye Neoplasms; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Uveitis, Anterior	2005
Chronic myelogenous leukemia in accelerated phase. Archives of pathology & laboratory medicine, 2005, Volume: 129, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fatal Outcome; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Middle Aged; Oxides; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic	2005
In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia. Anti-cancer drugs, 2005, Volume: 16, Issue:6 Topics: Adult; Antineoplastic Agents; Asparaginase; Benzamides; Cell Survival; Cytarabine; Daunorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Fluorometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mercaptopurine; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Pyrimidines; Tumor Cells, Cultured; Vincristine	2005
[Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2005, Volume: 26, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Clone Cells; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Treatment Outcome	2005
Philadelphia-chromosome positive thrombocythemia in a child. European journal of haematology, 2005, Volume: 75, Issue:3 Topics: Benzamides; Bone Marrow; Child; Female; Humans; Hydroxyurea; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocytosis	2005
CML clonal evolution with resistance to single agent imatinib therapy. Clinical and laboratory haematology, 2005, Volume: 27, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Transformation, Neoplastic; Clone Cells; Cytarabine; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Treatment Failure; Trisomy	2005
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. The Lancet. Oncology, 2005, Volume: 6, Issue:10 Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2005
Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation. Clinical nephrology, 2005, Volume: 64, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Follow-Up Studies; Humans; Imatinib Mesylate; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction	2005
Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4 Topics: Adult; Antineoplastic Agents; Benzamides; Brain Neoplasms; Glioblastoma; Humans; Imatinib Mesylate; Male; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2006
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica, 2005, Volume: 90 Suppl Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine	2005
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology. American Society of Hematology. Education Program, 2005 Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Stem Cell Transplantation; Survival Rate	2005
Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia. Cancer genetics and cytogenetics, 2005, Volume: 163, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2005
Pregnancy among patients with chronic myeloid leukemia treated with imatinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-01, Volume: 24, Issue:7 Topics: Abortion, Spontaneous; Adult; Antineoplastic Agents; Benzamides; Congenital Abnormalities; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Records; Metaphase; Philadelphia Chromosome; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Retrospective Studies; Teratogens	2006
Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia. Leukemia research, 2006, Volume: 30, Issue:10 Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Female; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Recombinant Proteins	2006
Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:5 Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Middle Aged; Philadelphia Chromosome; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Radiography	2006
Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia, 2006, Volume: 20, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Imatinib Mesylate; Methylprednisolone; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Treatment Outcome	2006
Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome? British journal of haematology, 2006, Volume: 135, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2006
Philadelphia chromosome unmasked as a secondary genetic change in acute myeloid leukemia on imatinib treatment. Leukemia, 2006, Volume: 20, Issue:11 Topics: Acute Disease; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines	2006
Presentation of extramedullary Philadelphia chromosome-positive biphenotypic acute leukemia as testicular mass: Response to imatinib-combined chemotherapy. Leukemia & lymphoma, 2006, Volume: 47, Issue:12 Topics: Antineoplastic Agents; Benzamides; Bone Marrow Cells; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Stem Cell Transplantation; Testicular Neoplasms; Transplantation, Homologous	2006
Leukaemic infiltration of the mandible in a young girl. International journal of paediatric dentistry, 2007, Volume: 17, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Child; Dexamethasone; Female; Humans; Imatinib Mesylate; Leukemic Infiltration; Mandible; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2007
Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation. American journal of hematology, 2007, Volume: 82, Issue:8 Topics: Adult; Benzamides; Chromosomes, Human, Pair 11; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Stem Cell Transplantation; Tissue Donors; Transplantation, Homologous	2007
An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment. Cancer genetics and cytogenetics, 2007, Apr-01, Volume: 174, Issue:1 Topics: Aged; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 16; Core Binding Factor beta Subunit; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2007
Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript. Cancer genetics and cytogenetics, 2007, Apr-15, Volume: 174, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosome Banding; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Transcription, Genetic; Treatment Outcome	2007
Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients. Cancer genetics and cytogenetics, 2007, Apr-15, Volume: 174, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Centromere; Chromosome Aberrations; Chromosome Banding; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines	2007
Successful treatment with imatinib combined with less intensive chemotherapy (vincristine and dexamethasone) as induction therapy in a very elderly patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. International journal of hematology, 2007, Volume: 85, Issue:3 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dexamethasone; Female; Genes, abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Vincristine	2007
Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells. Leukemia & lymphoma, 2007, Volume: 48, Issue:5 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetics; Hematopoietic Stem Cells; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines	2007
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica, 2007, Volume: 92, Issue:4 Topics: Adenosine Triphosphate; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Benzene Derivatives; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Hydroxamic Acids; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Naphthalenes; Panobinostat; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Structure-Activity Relationship; Threonine; Vorinostat	2007
Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia. Haematologica, 2007, Volume: 92, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosome Deletion; Clone Cells; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Monosomy; Neoplastic Cells, Circulating; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Remission Induction; Trisomy	2007
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clinical and experimental medicine, 2007, Volume: 7, Issue:2 Topics: Benzamides; Blood Cell Count; Blood Platelets; Cell Line; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; RNA, Small Interfering; Transcription, Genetic; Transfection	2007
Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia. Leukemia & lymphoma, 2007, Volume: 48, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous; Whole-Body Irradiation	2007
A case of Philadelphia-chromosome positive chronic idiopathic myelofibrosis. Leukemia research, 2008, Volume: 32, Issue:4 Topics: Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Piperazines; Primary Myelofibrosis; Pyrimidines	2008
Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. Acta haematologica, 2007, Volume: 118, Issue:3 Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Time Factors	2007
Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome. Leukemia & lymphoma, 2007, Volume: 48, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mosaicism; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome	2007
[The prognostic implications of secondary chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia patients after imatinib mesylate treatment]. Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosome Aberrations; Chromosome Banding; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines	2007
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Barbara Wassmann. Drugs, 2007, Volume: 67, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Salvage Therapy; Survival Rate; Treatment Outcome	2007
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Ronan Swords. Drugs, 2007, Volume: 67, Issue:17 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous	2007
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein. Drugs, 2007, Volume: 67, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous	2007
Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models. Bulletin of mathematical biology, 2008, Volume: 70, Issue:3 Topics: Antineoplastic Agents; Benzamides; Computer Simulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Philadelphia Chromosome; Piperazines; Pyrimidines	2008
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer, 2008, Feb-15, Volume: 112, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Survival Analysis; Time Factors; Transcription, Genetic; Translocation, Genetic; Treatment Outcome	2008
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood, 2008, Mar-01, Volume: 111, Issue:5 Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Benzodiazepines; Blast Crisis; Caspase 3; Cell Death; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles	2008
Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. Genes, chromosomes & cancer, 2008, Volume: 47, Issue:4 Topics: Benzamides; Biomarkers, Tumor; Blotting, Northern; Blotting, Western; Feedback, Physiological; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Oligonucleotide Array Sequence Analysis; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured	2008
Successful treatment with interferon-alpha-2b and imatinib in an adult Japanese male with Philadelphia chromosome-positive acute lymphoblastic leukemia and minimal residual disease following allogeneic transplantation. Bone marrow transplantation, 2008, Volume: 41, Issue:9 Topics: Antineoplastic Agents; Asian People; Benzamides; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recombinant Proteins; Remission Induction; Transplantation, Homologous	2008
Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib. Leukemia research, 2009, Volume: 33, Issue:3 Topics: Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction	2009
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leukemia research, 2009, Volume: 33, Issue:1 Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Lymphocyte Transfusion; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Stem Cell Transplantation	2009
[A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate]. Zhonghua nei ke za zhi, 2007, Volume: 46, Issue:12 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome	2007
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:7 Topics: Apoptosis; Benzamides; Cell Division; Cell Survival; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Pyrimidines; Tumor Cells, Cultured	1998
The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL. British journal of haematology, 1998, Volume: 103, Issue:3 Topics: Antigens, CD34; Apoptosis; Benzamides; Enzyme Inhibitors; fas Receptor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured	1998
Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Cell death and differentiation, 1998, Volume: 5, Issue:8 Topics: Apoptosis; Benzamides; Caspases; Enzyme Activation; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retinoblastoma Protein; Tumor Cells, Cultured; U937 Cells	1998
BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Molecular and cellular biology, 1999, Volume: 19, Issue:11 Topics: Animals; Benzamides; Cell Movement; Cell Transformation, Neoplastic; Down-Regulation; Fusion Proteins, bcr-abl; Half-Life; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Philadelphia Chromosome; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; src Homology Domains	1999
Promising clinical trials on kinase inhibitor. Trends in cell biology, 2001, Volume: 11, Issue:3 Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines	2001
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, N.Y.), 2001, Aug-03, Volume: 293, Issue:5531 Topics: Amino Acid Sequence; Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Benzamides; Blast Crisis; Cell Line; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Amplification; Genes, abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Philadelphia Chromosome; Phosphorylation; Piperazines; Point Mutation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-crk; Pyrimidines; Recurrence; Signal Transduction	2001
[Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results]. Bulletin du cancer, 2001, Volume: 88, Issue:7 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Stomach Neoplasms; Treatment Outcome	2001
Improving the management of chronic myeloid leukaemia. Hospital medicine (London, England : 1998), 2001, Volume: 62, Issue:9 Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines	2001
Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo. Leukemia research, 2001, Volume: 25, Issue:11 Topics: Antineoplastic Agents; Area Under Curve; Benzamides; Case-Control Studies; Cell Division; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Progenitor Cells; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Pyrimidines	2001
[STI571: the resistance organizes!]. Bulletin du cancer, 2001, Volume: 88, Issue:9 Topics: Antineoplastic Agents; Benzamides; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gene Amplification; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence	2001
Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571. Leukemia, 2001, Volume: 15, Issue:11 Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Ploidies; Pyrimidines	2001
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood, 2002, Jul-15, Volume: 100, Issue:2 Topics: Adult; Aged; Benzamides; Blood Cells; Bone Marrow Cells; Cytogenetic Analysis; Drug Resistance; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome	2002
Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia, 2002, Volume: 16, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 8; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Trisomy	2002
ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL). Leukemia, 2002, Volume: 16, Issue:7 Topics: Acute Disease; Antineoplastic Agents; Benzamides; Cell Lineage; Child; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy	2002